ID   BRCA2_HUMAN             Reviewed;        3418 AA.
AC   P51587; O00183; O15008; Q13879; Q5TBJ7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-NOV-2015, sequence version 3.
DT   11-DEC-2019, entry version 220.
DE   RecName: Full=Breast cancer type 2 susceptibility protein;
DE   AltName: Full=Fanconi anemia group D1 protein;
GN   Name=BRCA2; Synonyms=FACD, FANCD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8524414; DOI=10.1038/378789a0;
RA   Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J.,
RA   Collins N., Gregory S., Gumbs C., Micklem G., Barfoot R., Hamoudi R.,
RA   Patel S., Rice C., Biggs P., Hashim Y., Smith A., Connor F., Arason A.,
RA   Gudmundsson J., Ficenec D., Kelsell D., Ford D., Tonin P., Bishop D.T.,
RA   Spurr N.K., Ponder B.A.J., Eeles R., Peto J., Devilee P., Cornelisse C.,
RA   Lynch H., Narod S., Lenoir G., Egilsson V., Barkadottir R.B., Easton D.F.,
RA   Bentley D.R., Futreal P.A., Ashworth A., Stratton M.R.;
RT   "Identification of the breast cancer susceptibility gene BRCA2.";
RL   Nature 378:789-792(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS HIS-372 AND PHE-599.
RX   PubMed=8589730; DOI=10.1038/ng0396-333;
RA   Tavtigian S.V., Simard J., Rommens J., Couch F., Shattuck-Eidens D.,
RA   Neuhausen S., Merajver S., Thorlacius S., Offit K., Stoppa-Lyonnet D.,
RA   Belanger C., Bell R., Berry S., Bogden R., Chen Q., Davis T., Dumont M.,
RA   Frye C., Hattier T., Jammulapati S., Janecki T., Jiang P., Kehrer R.,
RA   Leblanc J.-F., Mitchell J.T., McArthur-Morrison J., Nguyen K., Peng Y.,
RA   Samson C., Schroeder M., Snyder S.C., Steele L., Stringfellow M.,
RA   Stroup C., Swedlund B., Swensen J., Teng D., Thomas A., Tran T., Tran T.,
RA   Tranchant M., Weaver-Feldhaus J., Wong A.K.C., Shizuya H., Eyfjord J.E.,
RA   Cannon-Albright L., Labrie F., Skolnick M.H., Weber B., Kamb A.,
RA   Goldar D.E.;
RT   "The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.";
RL   Nat. Genet. 12:333-337(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-289; GLN-322; HIS-372;
RP   VAL-784; SER-929; PHE-976; ILE-987; ASP-991; ASN-1561; LYS-1880; MET-1915;
RP   PHE-2138; ARG-2162; ARG-2440; VAL-2466; THR-2490; PRO-2835; ALA-2856;
RP   PHE-2944; THR-2951; ILE-3244 AND VAL-3412.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   INVOLVEMENT IN PNCA2.
RX   PubMed=9140390; DOI=10.1038/ng0597-17;
RA   Ozcelik H., Schmocker B., Di Nicola N., Shi X.H., Langer B., Moore M.,
RA   Taylor B.R., Narod S.A., Darlington G., Andrulis I.L., Gallinger S.,
RA   Redston M.;
RT   "Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer
RT   patients.";
RL   Nat. Genet. 16:17-18(1997).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH FANCD2.
RX   PubMed=15115758; DOI=10.1093/hmg/ddh135;
RA   Hussain S., Wilson J.B., Medhurst A.L., Hejna J., Witt E., Ananth S.,
RA   Davies A., Masson J.-Y., Moses R., West S.C., de Winter J.P., Ashworth A.,
RA   Jones N.J., Mathew C.G.;
RT   "Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways.";
RL   Hum. Mol. Genet. 13:1241-1248(2004).
RN   [7]
RP   INTERACTION WITH SEM1.
RX   PubMed=10373512;
RA   Marston N.J., Richards W.J., Hughes D., Bertwistle D., Marshall C.J.,
RA   Ashworth A.;
RT   "Interaction between the product of the breast cancer susceptibility gene
RT   BRCA2 and DSS1, a protein functionally conserved from yeast to mammals.";
RL   Mol. Cell. Biol. 19:4633-4642(1999).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH FANCD2.
RX   PubMed=15199141; DOI=10.1128/MCB.24.13.5850-5862.2004;
RA   Wang X.Z., Andreassen P.R., D'Andrea A.D.;
RT   "Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in
RT   chromatin.";
RL   Mol. Cell. Biol. 24:5850-5862(2004).
RN   [9]
RP   INVOLVEMENT IN GLM3.
RX   PubMed=15689453; DOI=10.1136/jmg.2004.022673;
RG   The famillial Wilms tumor collaboration;
RA   Reid S., Renwick A., Seal S., Baskcomb L., Barfoot R., Jayatilake H.,
RA   Pritchard-Jones K., Stratton M.R., Ridolfi-Luethy A., Rahman N.;
RT   "Biallelic BRCA2 mutations are associated with multiple malignancies in
RT   childhood including familial Wilms tumour.";
RL   J. Med. Genet. 42:147-151(2005).
RN   [10]
RP   UBIQUITINATION, DEUBIQUITINATION, AND INTERACTION WITH USP11.
RX   PubMed=15314155; DOI=10.1128/MCB.24.17.7444-7455.2004;
RA   Schoenfeld A.R., Apgar S., Dolios G., Wang R., Aaronson S.A.;
RT   "BRCA2 is ubiquitinated in vivo and interacts with USP11, a
RT   deubiquitinating enzyme that exhibits prosurvival function in the cellular
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 24:7444-7455(2004).
RN   [11]
RP   FUNCTION.
RX   PubMed=15671039; DOI=10.1074/jbc.M414669200;
RA   Ohashi A., Zdzienicka M.Z., Chen J., Couch F.J.;
RT   "FANCD2 functions independently of BRCA2 and RAD51 associated homologous
RT   recombination in response to DNA damage.";
RL   J. Biol. Chem. 280:14877-14883(2005).
RN   [12]
RP   INTERACTION WITH WDR16.
RX   PubMed=15967112; DOI=10.1593/neo.04544;
RA   Silva F.P., Hamamoto R., Nakamura Y., Furukawa Y.;
RT   "WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human
RT   hepatocellular carcinoma and involved in cell proliferation.";
RL   Neoplasia 7:348-355(2005).
RN   [13]
RP   PHOSPHORYLATION AT SER-3291 BY CDK2, INTERACTION WITH RAD51, AND
RP   MUTAGENESIS OF SER-3291.
RX   PubMed=15800615; DOI=10.1038/nature03404;
RA   Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., West S.C.;
RT   "CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for
RT   recombinational repair.";
RL   Nature 434:598-604(2005).
RN   [14]
RP   INTERACTION WITH PALB2, AND CHARACTERIZATION OF VARIANTS BC ARG-25; CYS-31
RP   AND ARG-31.
RX   PubMed=16793542; DOI=10.1016/j.molcel.2006.05.022;
RA   Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X.,
RA   Jasin M., Couch F.J., Livingston D.M.;
RT   "Control of BRCA2 cellular and clinical functions by a nuclear partner,
RT   PALB2.";
RL   Mol. Cell 22:719-729(2006).
RN   [15]
RP   INTERACTION WITH SEM1.
RX   PubMed=16205630; DOI=10.1038/sj.onc.1209153;
RA   Li J., Zou C., Bai Y., Wazer D.E., Band V., Gao Q.;
RT   "DSS1 is required for the stability of BRCA2.";
RL   Oncogene 25:1186-1194(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-755, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION IN A BRCA COMPLEX
RP   WITH BRCA1 AND PALB2.
RX   PubMed=19369211; DOI=10.1073/pnas.0811159106;
RA   Sy S.M., Huen M.S., Chen J.;
RT   "PALB2 is an integral component of the BRCA complex required for homologous
RT   recombination repair.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:7155-7160(2009).
RN   [18]
RP   INTERACTION WITH FANCD2; FANCG AND XRCC3.
RX   PubMed=18212739; DOI=10.1038/sj.onc.1211034;
RA   Wilson J.B., Yamamoto K., Marriott A.S., Hussain S., Sung P., Hoatlin M.E.,
RA   Mathew C.G., Takata M., Thompson L.H., Kupfer G.M., Jones N.J.;
RT   "FANCG promotes formation of a newly identified protein complex containing
RT   BRCA2, FANCD2 and XRCC3.";
RL   Oncogene 27:3641-3652(2008).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH RAD51.
RX   PubMed=20729859; DOI=10.1038/nsmb.1904;
RA   Liu J., Doty T., Gibson B., Heyer W.D.;
RT   "Human BRCA2 protein promotes RAD51 filament formation on RPA-covered
RT   single-stranded DNA.";
RL   Nat. Struct. Mol. Biol. 17:1260-1262(2010).
RN   [20]
RP   FUNCTION IN RAD51-DEPENDENT DNA REPAIR, PHOSPHORYLATION AT THR-3387 BY
RP   CHEK1 AND CHEK2, MUTAGENESIS OF THR-3387, AND INTERACTION WITH RAD51.
RX   PubMed=18317453; DOI=10.1038/onc.2008.17;
RA   Bahassi E.M., Ovesen J.L., Riesenberg A.L., Bernstein W.Z., Hasty P.E.,
RA   Stambrook P.J.;
RT   "The checkpoint kinases Chk1 and Chk2 regulate the functional associations
RT   between hBRCA2 and Rad51 in response to DNA damage.";
RL   Oncogene 27:3977-3985(2008).
RN   [21]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=20729858; DOI=10.1038/nsmb.1905;
RA   Thorslund T., McIlwraith M.J., Compton S.A., Lekomtsev S., Petronczki M.,
RA   Griffith J.D., West S.C.;
RT   "The breast cancer tumor suppressor BRCA2 promotes the specific targeting
RT   of RAD51 to single-stranded DNA.";
RL   Nat. Struct. Mol. Biol. 17:1263-1265(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, AND INTERACTION WITH RAD51
RP   AND DMC1.
RX   PubMed=20729832; DOI=10.1038/nature09399;
RA   Jensen R.B., Carreira A., Kowalczykowski S.C.;
RT   "Purified human BRCA2 stimulates RAD51-mediated recombination.";
RL   Nature 467:678-683(2010).
RN   [23]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21276791; DOI=10.1016/j.yexcr.2011.01.021;
RA   Cappelli E., Townsend S., Griffin C., Thacker J.;
RT   "Homologous recombination proteins are associated with centrosomes and are
RT   required for mitotic stability.";
RL   Exp. Cell Res. 317:1203-1213(2011).
RN   [24]
RP   FUNCTION, AND INTERACTION WITH ROCK2 AND NPM1.
RX   PubMed=21084279; DOI=10.1158/0008-5472.CAN-10-0030;
RA   Wang H.F., Takenaka K., Nakanishi A., Miki Y.;
RT   "BRCA2 and nucleophosmin coregulate centrosome amplification and form a
RT   complex with the Rho effector kinase ROCK2.";
RL   Cancer Res. 71:68-77(2011).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH POLH.
RX   PubMed=24485656; DOI=10.1016/j.celrep.2014.01.009;
RA   Buisson R., Niraj J., Pauty J., Maity R., Zhao W., Coulombe Y., Sung P.,
RA   Masson J.Y.;
RT   "Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in
RT   recombination-associated DNA synthesis at blocked replication forks.";
RL   Cell Rep. 6:553-564(2014).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-70; SER-445; SER-492;
RP   SER-1970; THR-2035; SER-2095 AND SER-3319, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   INTERACTION WITH SEM1, CHARACTERIZATION OF VARIANT BC HIS-2723, MUTAGENESIS
RP   OF TRP-2725, NUCLEAR EXPORT SIGNAL, AND SUBCELLULAR LOCATION.
RX   PubMed=24013206; DOI=10.1038/nsmb.2666;
RA   Jeyasekharan A.D., Liu Y., Hattori H., Pisupati V., Jonsdottir A.B.,
RA   Rajendra E., Lee M., Sundaramoorthy E., Schlachter S., Kaminski C.F.,
RA   Ofir-Rosenfeld Y., Sato K., Savill J., Ayoub N., Venkitaraman A.R.;
RT   "A cancer-associated BRCA2 mutation reveals masked nuclear export signals
RT   controlling localization.";
RL   Nat. Struct. Mol. Biol. 20:1191-1198(2013).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 21-39 IN COMPLEX WITH PALB2.
RX   PubMed=19609323; DOI=10.1038/embor.2009.126;
RA   Oliver A.W., Swift S., Lord C.J., Ashworth A., Pearl L.H.;
RT   "Structural basis for recruitment of BRCA2 by PALB2.";
RL   EMBO Rep. 10:990-996(2009).
RN   [29]
RP   INTERACTION WITH PALB2, AND IDENTIFICATION IN A PALB2-CONTAINING HR
RP   COMPLEX.
RX   PubMed=24141787; DOI=10.1038/onc.2013.421;
RA   Park J.Y., Singh T.R., Nassar N., Zhang F., Freund M., Hanenberg H.,
RA   Meetei A.R., Andreassen P.R.;
RT   "Breast cancer-associated missense mutants of the PALB2 WD40 domain, which
RT   directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.";
RL   Oncogene 33:4803-4812(2014).
RN   [30]
RP   FUNCTION IN R-LOOP PROCESSING, AND INTERACTION WITH SEM1 AND PCID2.
RX   PubMed=24896180; DOI=10.1038/nature13374;
RA   Bhatia V., Barroso S.I., Garcia-Rubio M.L., Tumini E., Herrera-Moyano E.,
RA   Aguilera A.;
RT   "BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export
RT   factor PCID2.";
RL   Nature 511:362-365(2014).
RN   [31]
RP   INTERACTION WITH PALB2.
RX   PubMed=28319063; DOI=10.1038/onc.2017.46;
RA   Foo T.K., Tischkowitz M., Simhadri S., Boshari T., Zayed N., Burke K.A.,
RA   Berman S.H., Blecua P., Riaz N., Huo Y., Ding Y.C., Neuhausen S.L.,
RA   Weigelt B., Reis-Filho J.S., Foulkes W.D., Xia B.;
RT   "Compromised BRCA1-PALB2 interaction is associated with breast cancer
RT   risk.";
RL   Oncogene 36:4161-4170(2017).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 1519-1551 IN COMPLEX WITH RAD51.
RX   PubMed=12442171; DOI=10.1038/nature01230;
RA   Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L.,
RA   Venkitaraman A.R.;
RT   "Insights into DNA recombination from the structure of a RAD51-BRCA2
RT   complex.";
RL   Nature 420:287-293(2002).
RN   [33]
RP   VARIANT OVARIAN CANCER HIS-2787, AND VARIANTS HIS-372; MET-1915 AND
RP   VAL-2466.
RX   PubMed=8665505;
RA   Takahashi H., Chiu H.-C., Bandera C.A., Behbakht K., Liu P.C., Couch F.J.,
RA   Weber B.L., LiVolsi V.A., Furusato M., Rebane B.A., Cardonick A.,
RA   Benjamin I., Morgan M.A., King S.A., Mikuta J.J., Rubin S.C., Boyd J.;
RT   "Mutations of the BRCA2 gene in ovarian carcinomas.";
RL   Cancer Res. 56:2738-2741(1996).
RN   [34]
RP   VARIANTS HIS-372; ASP-991; SER-1147; MET-1915 AND CYS-2034.
RX   PubMed=8673091; DOI=10.1038/ng0596-123;
RA   Couch F.J., Farid L.M., Deshano M.L., Tavtigian S.V., Calzone K.,
RA   Campeau L., Peng Y., Bogden B., Chen Q., Neuhausen S., Shattuck-Eidens D.,
RA   Godwin A.K., Daly M., Radford D.M., Sedlacek S., Rommens J., Simard J.,
RA   Garber J., Merajver S., Weber B.L.;
RT   "BRCA2 germline mutations in male breast cancer cases and breast cancer
RT   families.";
RL   Nat. Genet. 13:123-125(1996).
RN   [35]
RP   VARIANT GLU-3095.
RX   PubMed=8640235; DOI=10.1038/ng0696-238;
RA   Lancaster J.M., Wooster R., Mangion J., Phelan C.M., Cochran C., Gumbs C.,
RA   Seal S., Barfoot R., Collins N., Bignell G., Patel S., Hamoudi R.,
RA   Larsson C., Wiseman R.W., Berchuck A., Iglehart J.D., Marks J.R.,
RA   Ashworth A., Stratton M.R., Futreal P.A.;
RT   "BRCA2 mutations in primary breast and ovarian cancers.";
RL   Nat. Genet. 13:238-240(1996).
RN   [36]
RP   VARIANTS.
RX   PubMed=8640236; DOI=10.1038/ng0696-241;
RA   Teng D.H.-F., Bogden R., Mitchell J., Baumgard M., Bell R., Berry S.,
RA   Davis T., Ha P.C., Kehrer R., Jammulapati S., Chen Q., Offit K.,
RA   Skolnick M.H., Tavtigian S.V., Jhanwar S., Swedlund B., Wong A.K.C.,
RA   Kamb A.;
RT   "Low incidence of BRCA2 mutations in breast carcinoma and other cancers.";
RL   Nat. Genet. 13:241-244(1996).
RN   [37]
RP   VARIANT BC ASN-2415.
RX   PubMed=8640237; DOI=10.1038/ng0696-245;
RA   Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y.;
RT   "Mutation analysis in the BRCA2 gene in primary breast cancers.";
RL   Nat. Genet. 13:245-247(1996).
RN   [38]
RP   VARIANT BC ASP-2089, AND VARIANT VAL-3412.
RX   PubMed=9150152;
RA   Vehmanen P., Friedman L.S., Eerola H., Sarantaus L., Pyrhoenen S.,
RA   Ponder B.A.J., Muhonen T., Nevanlinna H.;
RT   "A low proportion of BRCA2 mutations in Finnish breast cancer families.";
RL   Am. J. Hum. Genet. 60:1050-1058(1997).
RN   [39]
RP   VARIANT BC/PANCREAS CANCER TRP-554.
RX   PubMed=9654203; DOI=10.1007/s004390050738;
RA   Ganguly T., Dhulipala R., Godmilow L., Ganguly A.;
RT   "High throughput fluorescence-based conformation-sensitive gel
RT   electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an
RT   overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast
RT   cancer families.";
RL   Hum. Genet. 102:549-556(1998).
RN   [40]
RP   VARIANTS BC LEU-32; ARG-53; LEU-81; ARG-201; ALA-211; SER-222 AND THR-3118.
RX   PubMed=9609997; DOI=10.1007/s100380050035;
RA   Katagiri T., Kasumi F., Yoshimoto M., Nomizu T., Asaishi K., Abe R.,
RA   Tsuchiya A., Sugano M., Takai S., Yoneda M., Fukutomi T., Nanba K.,
RA   Makita M., Okazaki H., Hirata K., Okazaki M., Furutsuma Y., Morishita Y.,
RA   Iino Y., Karino T., Ayabe H., Hara S., Kajiwara T., Houga S., Shimizu T.,
RA   Toda M., Yamazaki Y., Uchida T., Kunitomo K., Sonoo H., Kurebayashi J.,
RA   Shimotsuma K., Nakamura Y., Miki Y.;
RT   "High proportion of missense mutations of the BRCA1 and BRCA2 genes in
RT   Japanese breast cancer families.";
RL   J. Hum. Genet. 43:42-48(1998).
RN   [41]
RP   VARIANTS OVARIAN CANCER PRO-75; HIS-2502 AND HIS-3098.
RX   PubMed=10486320; DOI=10.1086/302583;
RA   Gayther S.A., Russell P., Harrington P., Antoniou A.C., Easton D.F.,
RA   Ponder B.A.J.;
RT   "The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian
RT   cancer: no evidence for other ovarian cancer-susceptibility genes.";
RL   Am. J. Hum. Genet. 65:1021-1029(1999).
RN   [42]
RP   VARIANTS HIS-289; HIS-372; ASP-991 AND VAL-3412.
RX   PubMed=10323242; DOI=10.1007/s004390050936;
RA   Li S.S.-L., Tseng H.-M., Yang T.-P., Liu C.-H., Teng S.-J., Huang H.-W.,
RA   Chen L.-M., Kao H.-W., Chen J.H., Tseng J.-N., Chen A., Hou M.-F.,
RA   Huang T.-J., Chang H.-T., Mok K.-T., Tsai J.-H.;
RT   "Molecular characterization of germline mutations in the BRCA1 and BRCA2
RT   genes from breast cancer families in Taiwan.";
RL   Hum. Genet. 104:201-204(1999).
RN   [43]
RP   VARIANTS BC, AND VARIANTS.
RX   PubMed=9971877; DOI=10.1093/hmg/8.3.413;
RA   Wagner T.M.U., Hirtenlehner K., Shen P., Moeslinger R., Muhr D.,
RA   Fleischmann E., Concin H., Doeller W., Haid A., Lang A.H., Mayer P.,
RA   Petru E., Ropp E., Langbauer G., Kubista E., Scheiner O., Underhill P.,
RA   Mountain J., Stierer M., Zielinski C., Oefner P.;
RT   "Global sequence diversity of BRCA2: analysis of 71 breast cancer families
RT   and 95 control individuals of worldwide populations.";
RL   Hum. Mol. Genet. 8:413-423(1999).
RN   [44]
RP   VARIANT BC ARG-326, AND VARIANT ILE-2728.
RX   PubMed=10399947;
RX   DOI=10.1002/(SICI)1097-0215(19990730)82:3<325::AID-IJC3>3.0.CO;2-G;
RA   Sinilnikova O.M., Egan K.M., Quinn J.L., Boutrand L., Lenoir G.M.,
RA   Stoppa-Lyonnet D., Desjardins L., Levy C., Goldgar D., Gragoudas E.S.;
RT   "Germline brca2 sequence variants in patients with ocular melanoma.";
RL   Int. J. Cancer 82:325-328(1999).
RN   [45]
RP   ERRATUM.
RA   Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.;
RL   Am. J. Hum. Genet. 73:1477-1477(2002).
RN   [46]
RP   VARIANT HIS-372.
RX   PubMed=11062481; DOI=10.1038/81691;
RA   Healey C.S., Dunning A.M., Teare M.D., Chase D., Parker L., Burn J.,
RA   Chang-Claude J., Mannermaa A., Kataja V., Huntsman D.G., Pharoah P.D.P.,
RA   Luben R.N., Easton D.F., Ponder B.A.J.;
RT   "A common variant in BRCA2 is associated with both breast cancer risk and
RT   prenatal viability.";
RL   Nat. Genet. 26:362-364(2000).
RN   [47]
RP   VARIANTS BC MET-729; ILE-2515 AND ILE-2728, AND VARIANTS HIS-289; HIS-372;
RP   ASP-991; MET-1915 AND VAL-3412.
RX   PubMed=10978364; DOI=10.1136/jmg.37.9.e17;
RA   Plaschke J., Commer T., Jacobi C., Schackert H.K., Chang-Claude J.;
RT   "BRCA2 germline mutations among early onset breast cancer patients
RT   unselected for family history of the disease.";
RL   J. Med. Genet. 37:E17-E17(2000).
RN   [48]
RP   VARIANTS BC ASN-1179; ILE-3124 AND GLU-3196, AND VARIANT TYR-1420.
RX   PubMed=11139248; DOI=10.1002/1098-1004(2001)17:1<73::AID-HUMU12>3.3.CO;2-F;
RA   Kwiatkowska E., Teresiak M., Lamperska K.M., Karczewska A., Breborowicz D.,
RA   Stawicka M., Godlewski D., Krzyzosiak W.J., Mackiewicz A.;
RT   "BRCA2 germline mutations in male breast cancer patients in the Polish
RT   population.";
RL   Hum. Mutat. 17:73-73(2001).
RN   [49]
RP   VARIANTS BC THR-505; TYR-1730; HIS-2135 AND CYS-2222, AND VARIANT LYS-1880.
RX   PubMed=11241844; DOI=10.1002/humu.7;
RA   Edwards S.M., Kote-Jarai Z., Hamoudi R., Eeles R.A.;
RT   "An improved high throughput heteroduplex mutation detection system for
RT   screening BRCA2 mutations-fluorescent mutation detection (F-MD).";
RL   Hum. Mutat. 17:220-232(2001).
RN   [50]
RP   VARIANTS HIS-289 AND VAL-784, AND VARIANT BC GLU-3076.
RX   PubMed=11149425;
RA   Ikeda N., Miyoshi Y., Yoneda K., Shiba E., Sekihara Y., Kinoshita M.,
RA   Noguchi S.;
RT   "Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer
RT   families.";
RL   Int. J. Cancer 91:83-88(2001).
RN   [51]
RP   VARIANT BC ARG-2722.
RX   PubMed=12145750; DOI=10.1086/342192;
RA   Fackenthal J.D., Cartegni L., Krainer A.R., Olopade O.I.;
RT   "BRCA2 T2722R is a deleterious allele that causes exon skipping.";
RL   Am. J. Hum. Genet. 71:625-631(2002).
RN   [52]
RP   VARIANTS BC CYS-2072; CYS-2094 AND ASN-2128.
RX   PubMed=12373604; DOI=10.1038/sj.bjc.6600562;
RA   Jakubowska A., Nej K., Huzarski T., Scott R.J., Lubinski J.;
RT   "BRCA2 gene mutations in families with aggregations of breast and stomach
RT   cancers.";
RL   Br. J. Cancer 87:888-891(2002).
RN   [53]
RP   VARIANT THR-192.
RX   PubMed=12097290;
RA   Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M.,
RA   Bansal R., Hruban R.H., Kern S.E.;
RT   "Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial
RT   pancreatic cancer: deleterious BRCA2 mutations in 17%.";
RL   Cancer Res. 62:3789-3793(2002).
RN   [54]
RP   VARIANTS HIS-118; SER-315; ILE-1988; CYS-2842 AND SER-3300.
RX   PubMed=11948123;
RA   Hu N., Li G., Li W.-J., Wang C., Goldstein A.M., Tang Z.-Z., Roth M.J.,
RA   Dawsey S.M., Huang J., Wang Q.-H., Ding T., Giffen C., Taylor P.R.,
RA   Emmert-Buck M.R.;
RT   "Infrequent mutation in the BRCA2 gene in esophageal squamous cell
RT   carcinoma.";
RL   Clin. Cancer Res. 8:1121-1126(2002).
RN   [55]
RP   VARIANTS ALA-598; TYR-1420; CYS-2034; ILE-2728 AND THR-2951.
RX   PubMed=12215251; DOI=10.1089/10906570260199375;
RA   Deffenbaugh A.M., Frank T.S., Hoffman M., Cannon-Albright L.,
RA   Neuhausen S.L.;
RT   "Characterization of common BRCA1 and BRCA2 variants.";
RL   Genet. Test. 6:119-121(2002).
RN   [56]
RP   VARIANTS ASP-1593 AND SER-2706.
RX   PubMed=12442273; DOI=10.1002/humu.9082;
RA   Saxena S., Szabo C.I., Chopin S., Barjhoux L., Sinilnikova O., Lenoir G.,
RA   Goldgar D.E., Bhatanager D.;
RT   "BRCA1 and BRCA2 in Indian breast cancer patients.";
RL   Hum. Mutat. 20:473-474(2002).
RN   [57]
RP   VARIANT BC ASN-2729, AND VARIANT VAL-3412.
RX   PubMed=12442274; DOI=10.1002/humu.9083;
RA   Zhi X., Szabo C., Chopin S., Suter N., Wang Q.-S., Ostrander E.A.,
RA   Sinilnikova O.M., Lenoir G.M., Goldgar D., Shi Y.-R.;
RT   "BRCA1 and BRCA2 sequence variants in Chinese breast cancer families.";
RL   Hum. Mutat. 20:474-474(2002).
RN   [58]
RP   VARIANTS BC CYS-42; ARG-613; LEU-2118; LEU-2293 AND ARG-2793, AND VARIANT
RP   ILE-3374.
RX   PubMed=12442275; DOI=10.1002/humu.9084;
RA   Ruiz-Flores P., Sinilnikova O.M., Badzioch M., Calderon-Garciduenas A.L.,
RA   Chopin S., Fabrice O., Gonzalez-Guerrero J.F., Szabo C., Lenoir G.,
RA   Goldgar D.E., Barrera-Saldana H.A.;
RT   "BRCA1 and BRCA2 mutation analysis of early-onset and familial breast
RT   cancer cases in Mexico.";
RL   Hum. Mutat. 20:474-475(2002).
RN   [59]
RP   VARIANT FANCD1 PRO-2510.
RX   PubMed=14670928; DOI=10.1182/blood-2003-06-1970;
RA   Hirsch B., Shimamura A., Moreau L., Baldinger S., Hag-alshiekh M.,
RA   Bostrom B., Sencer S., D'Andrea A.D.;
RT   "Association of biallelic BRCA2/FANCD1 mutations with spontaneous
RT   chromosomal instability and solid tumors of childhood.";
RL   Blood 103:2554-2559(2004).
RN   [60]
RP   VARIANTS BC TYR-1580 AND MET-1915.
RX   PubMed=11948477; DOI=10.1002/ijc.10289;
RA   Kwiatkowska E., Teresiak M., Breborowicz D., Mackiewicz A.;
RT   "Somatic mutations in the BRCA2 gene and high frequency of allelic loss of
RT   BRCA2 in sporadic male breast cancer.";
RL   Int. J. Cancer 98:943-945(2002).
RN   [61]
RP   VARIANTS BC SER-60; ARG-405; HIS-448; GLY-462; GLY-2275; ARG-2353;
RP   LYS-2488; HIS-2723; ASN-2950; ILE-3013 AND HIS-3098, AND VARIANTS ASP-991;
RP   ALA-2856 AND VAL-3412.
RX   PubMed=15026808; DOI=10.1038/sj.bjc.6601656;
RA   Claes K., Poppe B., Coene I., De Paepe A., Messiaen L.;
RT   "BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian
RT   breast/ovarian cancer families.";
RL   Br. J. Cancer 90:1244-1251(2004).
RN   [62]
RP   INVOLVEMENT IN FANCD1.
RX   PubMed=12065746; DOI=10.1126/science.1073834;
RA   Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q.,
RA   de Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H.,
RA   Fox E.A., D'Andrea A.D.;
RT   "Biallelic inactivation of BRCA2 in Fanconi anemia.";
RL   Science 297:606-609(2002).
RN   [63]
RP   VARIANTS BC ILE-64; GLY-462; ASN-1690; ASP-1771; MET-1887; MET-1915 AND
RP   GLU-2456, AND VARIANTS HIS-289; HIS-372; ASP-991; SER-1279; TYR-1420;
RP   CYS-2108 AND VAL-2466.
RX   PubMed=15172753; DOI=10.1016/j.cancergencyto.2003.09.020;
RA   Hadjisavvas A., Charalambous E., Adamou A., Neuhausen S.L.,
RA   Christodoulou C.G., Kyriacou K.;
RT   "Hereditary breast and ovarian cancer in Cyprus: identification of a
RT   founder BRCA2 mutation.";
RL   Cancer Genet. Cytogenet. 151:152-156(2004).
RN   [64]
RP   VARIANTS HIS-289; HIS-372; GLY-462; ASP-991; SER-1279; TYR-1420; ASP-1771
RP   AND VAL-2466.
RX   PubMed=12552570; DOI=10.1002/humu.9110;
RA   Hadjisavvas A., Charalambous E., Adamou A., Christodoulou C.G.,
RA   Kyriacou K.;
RT   "BRCA2 germline mutations in Cypriot patients with familial breast/ovarian
RT   cancer.";
RL   Hum. Mutat. 21:171-171(2003).
RN   [65]
RP   VARIANT OVARIAN CANCER CYS-42, AND VARIANTS SER-3063 AND VAL-3412.
RX   PubMed=14746861; DOI=10.1016/j.ejca.2003.09.016;
RA   Malander S., Ridderheim M., Masbaeck A., Loman N., Kristoffersson U.,
RA   Olsson H., Nilbert M., Borg A.;
RT   "One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2
RT   mutations: results of a prospective study in Southern Sweden.";
RL   Eur. J. Cancer 40:422-428(2004).
RN   [66]
RP   VARIANTS BC ILE-431; LYS-1036; ARG-1106 AND VAL-1524.
RX   PubMed=12938098; DOI=10.1002/humu.9174;
RA   Meyer P., Voigtlaender T., Bartram C.R., Klaes R.;
RT   "Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or
RT   ovarian cancer families in Southern Germany.";
RL   Hum. Mutat. 22:259-259(2003).
RN   [67]
RP   VARIANTS BC ILE-1679; ALA-1804; LYS-1901 AND LEU-2096.
RX   PubMed=14722926; DOI=10.1002/humu.9213;
RA   Valarmathi M.T., Sawhney M., Deo S.S.V., Shukla N.K., Das S.N.;
RT   "Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and
RT   breast-ovarian cancer families.";
RL   Hum. Mutat. 23:205-205(2004).
RN   [68]
RP   VARIANTS PRO-582; PHE-1522 AND VAL-2044.
RX   PubMed=12624724; DOI=10.1007/s100380300020;
RA   Sakayori M., Kawahara M., Shiraishi K., Nomizu T., Shimada A., Kudo T.,
RA   Abe R., Ohuchi N., Takenoshita S., Kanamaru R., Ishioka C.;
RT   "Evaluation of the diagnostic accuracy of the stop codon (SC) assay for
RT   identifying protein-truncating mutations in the BRCA1and BRCA2genes in
RT   familial breast cancer.";
RL   J. Hum. Genet. 48:130-137(2003).
RN   [69]
RP   VARIANT ALA-225, AND CHARACTERIZATION OF VARIANT ALA-225.
RX   PubMed=15300854; DOI=10.1002/humu.9267;
RA   Sharp A., Pichert G., Lucassen A., Eccles D.;
RT   "RNA analysis reveals splicing mutations and loss of expression defects in
RT   MLH1 and BRCA1.";
RL   Hum. Mutat. 24:272-272(2004).
RN   [70]
RP   VARIANT CYS-2034, AND VARIANT BC GLU-3076.
RX   PubMed=12569143; DOI=10.1093/jnci/95.3.214;
RA   Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B.,
RA   Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D., Gruetzmann R.,
RA   Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P., Bartsch D.K.;
RT   "BRCA2 germline mutations in familial pancreatic carcinoma.";
RL   J. Natl. Cancer Inst. 95:214-221(2003).
RN   [71]
RP   VARIANTS BC THR-1445; VAL-1929 AND ALA-2031, AND VARIANTS HIS-289; HIS-372;
RP   VAL-784; ASP-991 AND VAL-3412.
RX   PubMed=15365993; DOI=10.1002/humu.9275;
RA   Seo J.H., Cho D.-Y., Ahn S.-H., Yoon K.-S., Kang C.-S., Cho H.M., Lee H.S.,
RA   Choe J.J., Choi C.W., Kim B.S., Shin S.W., Kim Y.H., Kim J.S., Son G.-S.,
RA   Lee J.-B., Koo B.H.;
RT   "BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast
RT   cancer.";
RL   Hum. Mutat. 24:350-350(2004).
RN   [72]
RP   VARIANTS LEU-1172; TYR-1420; PHE-2944; ASN-2950 AND ILE-3013.
RX   PubMed=15635067; DOI=10.1136/jmg.2004.025056;
RA   Kim S.-W., Lee C.S., Fey J.V., Borgen P.I., Boyd J.;
RT   "Prevalence of BRCA2 mutations in a hospital based series of unselected
RT   breast cancer cases.";
RL   J. Med. Genet. 42:E5-E5(2005).
RN   [73]
RP   VARIANTS HIS-2336; CYS-2502; CYS-2626; PHE-2627; PRO-2653; LYS-2659;
RP   VAL-2663; ARG-2722; GLY-2723; ASP-2748 AND GLU-3095.
RX   PubMed=17924331; DOI=10.1086/521032;
RA   Easton D.F., Deffenbaugh A.M., Pruss D., Frye C., Wenstrup R.J.,
RA   Allen-Brady K., Tavtigian S.V., Monteiro A.N.A., Iversen E.S., Couch F.J.,
RA   Goldgar D.E.;
RT   "A systematic genetic assessment of 1,433 sequence variants of unknown
RT   clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition
RT   genes.";
RL   Am. J. Hum. Genet. 81:873-883(2007).
RN   [74]
RP   VARIANTS FANCD1 HIS-2336 AND CYS-2626.
RX   PubMed=16825431; DOI=10.1136/jmg.2006.043257;
RA   Alter B.P., Rosenberg P.S., Brody L.C.;
RT   "Clinical and molecular features associated with biallelic mutations in
RT   FANCD1/BRCA2.";
RL   J. Med. Genet. 44:1-9(2007).
RN   [75]
RP   CHARACTERIZATION OF VARIANTS VAL-2663; GLY-2723 AND TRP-3052.
RX   PubMed=20513136; DOI=10.1002/humu.21267;
RA   Walker L.C., Whiley P.J., Couch F.J., Farrugia D.J., Healey S.,
RA   Eccles D.M., Lin F., Butler S.A., Goff S.A., Thompson B.A., Lakhani S.R.,
RA   Da Silva L.M., Tavtigian S.V., Goldgar D.E., Brown M.A., Spurdle A.B.;
RT   "Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence
RT   variants encoding missense substitutions: implications for prediction of
RT   pathogenicity.";
RL   Hum. Mutat. 31:E1484-E1505(2010).
RN   [76]
RP   VARIANTS LEU-606 AND TYR-1420.
RX   PubMed=26566883; DOI=10.1136/jmedgenet-2015-103179;
RA   Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G.,
RA   Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.;
RT   "Homozygous missense mutation in the LMAN2L gene segregates with
RT   intellectual disability in a large consanguineous Pakistani family.";
RL   J. Med. Genet. 53:138-144(2016).
RN   [77]
RP   CHARACTERIZATION OF VARIANTS FANCD1 HIS-2336; PRO-2510 AND CYS-2626,
RP   CHARACTERIZATION OF VARIANTS THR-2490 AND ASN-2729, FUNCTION, AND
RP   INTERACTION WITH SEM1.
RX   PubMed=21719596; DOI=10.1182/blood-2010-12-324541;
RA   Biswas K., Das R., Alter B.P., Kuznetsov S.G., Stauffer S., North S.L.,
RA   Burkett S., Brody L.C., Meyer S., Byrd R.A., Sharan S.K.;
RT   "A comprehensive functional characterization of BRCA2 variants associated
RT   with Fanconi anemia using mouse ES cell-based assay.";
RL   Blood 118:2430-2442(2011).
RN   [78]
RP   CHARACTERIZATION OF VARIANTS BC PHE-2627; PRO-2653; ARG-2722; GLY-2723;
RP   HIS-2723; ASN-2729; HIS-2787; PRO-2792; ARG-2793; ALA-2856; THR-2951;
RP   ILE-3013; TRP-3052; GLU-3076; GLU-3095; HIS-3098 AND ILE-3124,
RP   CHARACTERIZATION OF VARIANTS ARG-2440; VAL-2466; CYS-2842 AND SER-3063, AND
RP   CHARACTERIZATION OF VARIANT FANCD1 PRO-2510 AND CYS-2626.
RX   PubMed=23108138; DOI=10.1158/0008-5472.CAN-12-2081;
RA   Guidugli L., Pankratz V.S., Singh N., Thompson J., Erding C.A., Engel C.,
RA   Schmutzler R., Domchek S., Nathanson K., Radice P., Singer C., Tonin P.N.,
RA   Lindor N.M., Goldgar D.E., Couch F.J.;
RT   "A classification model for BRCA2 DNA binding domain missense variants
RT   based on homology-directed repair activity.";
RL   Cancer Res. 73:265-275(2013).
CC   -!- FUNCTION: Involved in double-strand break repair and/or homologous
CC       recombination. Binds RAD51 and potentiates recombinational DNA repair
CC       by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts
CC       by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to
CC       displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-
CC       ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded
CC       HR complex containing RAD51C and which is thought to play a role in DNA
CC       repair by HR. May participate in S phase checkpoint activation. Binds
CC       selectively to ssDNA, and to ssDNA in tailed duplexes and replication
CC       fork structures. May play a role in the extension step after strand
CC       invasion at replication-dependent DNA double-strand breaks; together
CC       with PALB2 is involved in both POLH localization at collapsed
CC       replication forks and DNA polymerization activity. In concert with
CC       NPM1, regulates centrosome duplication. Interacts with the TREX-2
CC       complex (transcription and export complex 2) subunits PCID2 and SEM1,
CC       and is required to prevent R-loop-associated DNA damage and thus
CC       transcription-associated genomic instability. Silencing of BRCA2
CC       promotes R-loop accumulation at actively transcribed genes in
CC       replicating and non-replicating cells, suggesting that BRCA2 mediates
CC       the control of R-loop associated genomic instability, independently of
CC       its known role in homologous recombination (PubMed:24896180).
CC       {ECO:0000269|PubMed:15115758, ECO:0000269|PubMed:15199141,
CC       ECO:0000269|PubMed:15671039, ECO:0000269|PubMed:18317453,
CC       ECO:0000269|PubMed:20729832, ECO:0000269|PubMed:20729858,
CC       ECO:0000269|PubMed:20729859, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:24485656,
CC       ECO:0000269|PubMed:24896180}.
CC   -!- SUBUNIT: Monomer and dimer (PubMed:20729858). Interacts with RAD51;
CC       regulates RAD51 recruitment and function at sites of DNA repair
CC       (PubMed:12442171, PubMed:15800615, PubMed:18317453, PubMed:20729832,
CC       PubMed:20729859). Interacts with WDR16, USP11, DMC1, ROCK2 and NPM1
CC       (PubMed:15314155, PubMed:15967112, PubMed:20729832, PubMed:21084279).
CC       Interacts with SEM1; the interaction masks a nuclear export signal in
CC       BRCA2 (PubMed:10373512, PubMed:16205630, PubMed:21719596,
CC       PubMed:24013206). Interacts with both nonubiquitinated and
CC       monoubiquitinated FANCD2; this complex also includes XRCC3 and
CC       phosphorylated FANCG (PubMed:15115758, PubMed:15199141,
CC       PubMed:18212739). Part of a BRCA complex containing BRCA1, BRCA2 and
CC       PALB2 (PubMed:19369211). Interacts directly with PALB2 which may serve
CC       as a scaffold for a HR complex containing PALB2, BRCA2, RAD51C, RAD51
CC       and XRCC3 (PubMed:19369211, PubMed:24141787, PubMed:28319063,
CC       PubMed:16793542, PubMed:19609323). Interacts with BRCA1 only in the
CC       presence of PALB2 which serves as the bridging protein
CC       (PubMed:19369211). Interacts with POLH; the interaction is direct
CC       (PubMed:24485656). Interacts with the TREX-2 complex subunits PCID2 and
CC       SEM1 (PubMed:24896180, PubMed:21719596). {ECO:0000269|PubMed:10373512,
CC       ECO:0000269|PubMed:12442171, ECO:0000269|PubMed:15115758,
CC       ECO:0000269|PubMed:15199141, ECO:0000269|PubMed:15314155,
CC       ECO:0000269|PubMed:15800615, ECO:0000269|PubMed:15967112,
CC       ECO:0000269|PubMed:16205630, ECO:0000269|PubMed:16793542,
CC       ECO:0000269|PubMed:18212739, ECO:0000269|PubMed:18317453,
CC       ECO:0000269|PubMed:19369211, ECO:0000269|PubMed:19609323,
CC       ECO:0000269|PubMed:20729832, ECO:0000269|PubMed:20729858,
CC       ECO:0000269|PubMed:20729859, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:24013206,
CC       ECO:0000269|PubMed:24141787, ECO:0000269|PubMed:24485656,
CC       ECO:0000269|PubMed:24896180, ECO:0000269|PubMed:28319063}.
CC   -!- INTERACTION:
CC       P51587; P51587-1; NbExp=3; IntAct=EBI-79792, EBI-79792;
CC       P51587; Q14565: DMC1; NbExp=12; IntAct=EBI-79792, EBI-930865;
CC       P51587; Q9BXW9: FANCD2; NbExp=16; IntAct=EBI-79792, EBI-359343;
CC       P51587; Q9BXW9-2: FANCD2; NbExp=3; IntAct=EBI-79792, EBI-596878;
CC       P51587; Q9P0W2: HMG20B; NbExp=8; IntAct=EBI-79792, EBI-713401;
CC       P51587; Q86YC2: PALB2; NbExp=25; IntAct=EBI-79792, EBI-1222653;
CC       P51587; Q9NTI5: PDS5B; NbExp=26; IntAct=EBI-79792, EBI-1175604;
CC       P51587; Q9Y253: POLH; NbExp=6; IntAct=EBI-79792, EBI-2827270;
CC       P51587; Q06609: RAD51; NbExp=45; IntAct=EBI-79792, EBI-297202;
CC       P51587; Q06609-1: RAD51; NbExp=12; IntAct=EBI-79792, EBI-15557721;
CC       P51587; P60896: SEM1; NbExp=10; IntAct=EBI-79792, EBI-79819;
CC       P51587; P04637: TP53; NbExp=7; IntAct=EBI-79792, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24013206,
CC       ECO:0000305|PubMed:21276791}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:21276791}.
CC   -!- TISSUE SPECIFICITY: Highest levels of expression in breast and thymus,
CC       with slightly lower levels in lung, ovary and spleen.
CC   -!- PTM: Phosphorylated by ATM upon irradiation-induced DNA damage.
CC       Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51.
CC       Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when
CC       recombination is active, but increases as cells progress towards
CC       mitosis; this phosphorylation prevents homologous recombination-
CC       dependent repair during S phase and G2 by inhibiting RAD51 binding.
CC       {ECO:0000269|PubMed:15199141, ECO:0000269|PubMed:15800615,
CC       ECO:0000269|PubMed:18317453}.
CC   -!- PTM: Ubiquitinated in the absence of DNA damage; this does not lead to
CC       proteasomal degradation. In contrast, ubiquitination in response to DNA
CC       damage leads to proteasomal degradation. {ECO:0000269|PubMed:15314155}.
CC   -!- DISEASE: Breast cancer (BC) [MIM:114480]: A common malignancy
CC       originating from breast epithelial tissue. Breast neoplasms can be
CC       distinguished by their histologic pattern. Invasive ductal carcinoma is
CC       by far the most common type. Breast cancer is etiologically and
CC       genetically heterogeneous. Important genetic factors have been
CC       indicated by familial occurrence and bilateral involvement. Mutations
CC       at more than one locus can be involved in different families or even in
CC       the same case. {ECO:0000269|PubMed:10399947,
CC       ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:11139248,
CC       ECO:0000269|PubMed:11149425, ECO:0000269|PubMed:11241844,
CC       ECO:0000269|PubMed:11948477, ECO:0000269|PubMed:12145750,
CC       ECO:0000269|PubMed:12373604, ECO:0000269|PubMed:12442274,
CC       ECO:0000269|PubMed:12442275, ECO:0000269|PubMed:12569143,
CC       ECO:0000269|PubMed:12938098, ECO:0000269|PubMed:14722926,
CC       ECO:0000269|PubMed:15026808, ECO:0000269|PubMed:15172753,
CC       ECO:0000269|PubMed:15365993, ECO:0000269|PubMed:16793542,
CC       ECO:0000269|PubMed:23108138, ECO:0000269|PubMed:24013206,
CC       ECO:0000269|PubMed:8640237, ECO:0000269|PubMed:9150152,
CC       ECO:0000269|PubMed:9609997, ECO:0000269|PubMed:9654203,
CC       ECO:0000269|PubMed:9971877}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- DISEASE: Pancreatic cancer 2 (PNCA2) [MIM:613347]: A malignant neoplasm
CC       of the pancreas. Tumors can arise from both the exocrine and endocrine
CC       portions of the pancreas, but 95% of them develop from the exocrine
CC       portion, including the ductal epithelium, acinar cells, connective
CC       tissue, and lymphatic tissue. {ECO:0000269|PubMed:9140390}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Breast-ovarian cancer, familial, 2 (BROVCA2) [MIM:612555]: A
CC       condition associated with familial predisposition to cancer of the
CC       breast and ovaries. Characteristic features in affected families are an
CC       early age of onset of breast cancer (often before age 50), increased
CC       chance of bilateral cancers (cancer that develop in both breasts, or
CC       both ovaries, independently), frequent occurrence of breast cancer
CC       among men, increased incidence of tumors of other specific organs, such
CC       as the prostate. Note=Disease susceptibility is associated with
CC       variations affecting the gene represented in this entry.
CC   -!- DISEASE: Fanconi anemia complementation group D1 (FANCD1) [MIM:605724]:
CC       A disorder affecting all bone marrow elements and resulting in anemia,
CC       leukopenia and thrombopenia. It is associated with cardiac, renal and
CC       limb malformations, dermal pigmentary changes, and a predisposition to
CC       the development of malignancies. At the cellular level it is associated
CC       with hypersensitivity to DNA-damaging agents, chromosomal instability
CC       (increased chromosome breakage) and defective DNA repair.
CC       {ECO:0000269|PubMed:12065746, ECO:0000269|PubMed:14670928,
CC       ECO:0000269|PubMed:16825431, ECO:0000269|PubMed:21719596,
CC       ECO:0000269|PubMed:23108138}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Glioma 3 (GLM3) [MIM:613029]: Gliomas are benign or malignant
CC       central nervous system neoplasms derived from glial cells. They
CC       comprise astrocytomas and glioblastoma multiforme that are derived from
CC       astrocytes, oligodendrogliomas derived from oligodendrocytes and
CC       ependymomas derived from ependymocytes. {ECO:0000269|PubMed:15689453}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- WEB RESOURCE: Name=Fanconi Anemia Mutation Database;
CC       URL="http://www2.rockefeller.edu/fanconi/genes/jumpd1";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/brca2/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=BRCA2 entry;
CC       URL="https://en.wikipedia.org/wiki/BRCA2";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BRCA2ID164ch13q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X95152; CAA64484.1; -; Genomic_DNA.
DR   EMBL; X95153; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95154; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95155; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95156; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95157; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95158; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95159; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95160; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95161; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95162; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95163; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95164; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95165; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95166; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95167; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95168; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95169; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95170; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95171; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95172; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95173; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95174; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95175; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95176; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; X95177; CAA64484.1; JOINED; Genomic_DNA.
DR   EMBL; U43746; AAB07223.1; -; mRNA.
DR   EMBL; AY436640; AAQ97181.1; -; Genomic_DNA.
DR   EMBL; AL137247; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL445212; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z74739; CAA98995.2; -; Genomic_DNA.
DR   EMBL; Z73359; CAA97728.1; -; Genomic_DNA.
DR   CCDS; CCDS9344.1; -.
DR   PIR; G02334; G02334.
DR   RefSeq; NP_000050.2; NM_000059.3.
DR   PDB; 1N0W; X-ray; 1.70 A; B=1517-1551.
DR   PDB; 3EU7; X-ray; 2.20 A; X=21-39.
DR   PDBsum; 1N0W; -.
DR   PDBsum; 3EU7; -.
DR   SMR; P51587; -.
DR   BioGRID; 107142; 191.
DR   ComplexPortal; CPX-955; BRCC ubiquitin ligase complex.
DR   CORUM; P51587; -.
DR   DIP; DIP-24214N; -.
DR   ELM; P51587; -.
DR   IntAct; P51587; 56.
DR   MINT; P51587; -.
DR   STRING; 9606.ENSP00000369497; -.
DR   BindingDB; P51587; -.
DR   iPTMnet; P51587; -.
DR   PhosphoSitePlus; P51587; -.
DR   BioMuta; BRCA2; -.
DR   DMDM; 14424438; -.
DR   CPTAC; CPTAC-3279; -.
DR   CPTAC; CPTAC-3280; -.
DR   EPD; P51587; -.
DR   jPOST; P51587; -.
DR   MassIVE; P51587; -.
DR   PaxDb; P51587; -.
DR   PeptideAtlas; P51587; -.
DR   PRIDE; P51587; -.
DR   ProteomicsDB; 56340; -.
DR   DNASU; 675; -.
DR   Ensembl; ENST00000380152; ENSP00000369497; ENSG00000139618.
DR   Ensembl; ENST00000544455; ENSP00000439902; ENSG00000139618.
DR   GeneID; 675; -.
DR   KEGG; hsa:675; -.
DR   UCSC; uc001uub.2; human.
DR   CTD; 675; -.
DR   DisGeNET; 675; -.
DR   EuPathDB; HostDB:ENSG00000139618.14; -.
DR   GeneCards; BRCA2; -.
DR   GeneReviews; BRCA2; -.
DR   HGNC; HGNC:1101; BRCA2.
DR   HPA; HPA026815; -.
DR   MalaCards; BRCA2; -.
DR   MIM; 114480; phenotype.
DR   MIM; 600185; gene.
DR   MIM; 605724; phenotype.
DR   MIM; 612555; phenotype.
DR   MIM; 613029; phenotype.
DR   MIM; 613347; phenotype.
DR   neXtProt; NX_P51587; -.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 1331; Familial prostate cancer.
DR   Orphanet; 84; Fanconi anemia.
DR   Orphanet; 145; Hereditary breast and ovarian cancer syndrome.
DR   Orphanet; 227535; Hereditary breast cancer.
DR   Orphanet; 213524; Hereditary site-specific ovarian cancer syndrome.
DR   Orphanet; 319462; Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations.
DR   Orphanet; 654; Nephroblastoma.
DR   PharmGKB; PA25412; -.
DR   eggNOG; KOG4751; Eukaryota.
DR   eggNOG; ENOG410Y06W; LUCA.
DR   HOGENOM; HOG000139693; -.
DR   InParanoid; P51587; -.
DR   OrthoDB; 257485at2759; -.
DR   TreeFam; TF105041; -.
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5693554; Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA).
DR   Reactome; R-HSA-5693568; Resolution of D-loop Structures through Holliday Junction Intermediates.
DR   Reactome; R-HSA-5693579; Homologous DNA Pairing and Strand Exchange.
DR   Reactome; R-HSA-5693616; Presynaptic phase of homologous DNA pairing and strand exchange.
DR   Reactome; R-HSA-912446; Meiotic recombination.
DR   SignaLink; P51587; -.
DR   SIGNOR; P51587; -.
DR   ChiTaRS; BRCA2; human.
DR   EvolutionaryTrace; P51587; -.
DR   GeneWiki; BRCA2; -.
DR   GenomeRNAi; 675; -.
DR   Pharos; P51587; Tbio.
DR   PRO; PR:P51587; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P51587; protein.
DR   Bgee; ENSG00000139618; Expressed in 127 organ(s), highest expression level in secondary oocyte.
DR   ExpressionAtlas; P51587; baseline and differential.
DR   Genevisible; P51587; HS.
DR   GO; GO:0033593; C:BRCA2-MAGE-D1 complex; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0000800; C:lateral element; IDA:MGI.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0030141; C:secretory granule; IDA:UniProtKB.
DR   GO; GO:0043015; F:gamma-tubulin binding; IPI:UniProtKB.
DR   GO; GO:0010484; F:H3 histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0010485; F:H4 histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IDA:MGI.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0051298; P:centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IEA:Ensembl.
DR   GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; IDA:BHF-UCL.
DR   GO; GO:0008585; P:female gonad development; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IEA:Ensembl.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:UniProtKB.
DR   GO; GO:0043967; P:histone H4 acetylation; IDA:UniProtKB.
DR   GO; GO:0001833; P:inner cell mass cell proliferation; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0007141; P:male meiosis I; IEA:Ensembl.
DR   GO; GO:1990426; P:mitotic recombination-dependent replication fork processing; IMP:BHF-UCL.
DR   GO; GO:0033600; P:negative regulation of mammary gland epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IEA:Ensembl.
DR   GO; GO:0048478; P:replication fork protection; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0010225; P:response to UV-C; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0000722; P:telomere maintenance via recombination; IEA:Ensembl.
DR   CDD; cd04493; BRCA2DBD_OB1; 1.
DR   CDD; cd04495; BRCA2DBD_OB3; 1.
DR   DisProt; DP01869; -.
DR   InterPro; IPR015525; BRCA2.
DR   InterPro; IPR015252; BRCA2_hlx.
DR   InterPro; IPR036315; BRCA2_hlx_sf.
DR   InterPro; IPR015187; BRCA2_OB_1.
DR   InterPro; IPR015188; BRCA2_OB_3.
DR   InterPro; IPR002093; BRCA2_repeat.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR015205; Tower_dom.
DR   PANTHER; PTHR11289; PTHR11289; 4.
DR   Pfam; PF09169; BRCA-2_helical; 1.
DR   Pfam; PF09103; BRCA-2_OB1; 1.
DR   Pfam; PF09104; BRCA-2_OB3; 1.
DR   Pfam; PF00634; BRCA2; 8.
DR   Pfam; PF09121; Tower; 1.
DR   PIRSF; PIRSF002397; BRCA2; 1.
DR   SMART; SM01341; Tower; 1.
DR   SUPFAM; SSF50249; SSF50249; 3.
DR   SUPFAM; SSF81872; SSF81872; 1.
DR   PROSITE; PS50138; BRCA2_REPEAT; 8.
PE   1: Evidence at protein level;
KW   3D-structure; Cell cycle; Cytoplasm; Cytoskeleton; Disease mutation;
KW   DNA damage; DNA recombination; DNA repair; DNA-binding; Fanconi anemia;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Tumor suppressor; Ubl conjugation.
FT   CHAIN           1..3418
FT                   /note="Breast cancer type 2 susceptibility protein"
FT                   /id="PRO_0000064984"
FT   REPEAT          1002..1036
FT                   /note="BRCA2 1"
FT   REPEAT          1212..1246
FT                   /note="BRCA2 2"
FT   REPEAT          1421..1455
FT                   /note="BRCA2 3"
FT   REPEAT          1517..1551
FT                   /note="BRCA2 4"
FT   REPEAT          1664..1698
FT                   /note="BRCA2 5"
FT   REPEAT          1837..1871
FT                   /note="BRCA2 6"
FT   REPEAT          1971..2005
FT                   /note="BRCA2 7"
FT   REPEAT          2051..2085
FT                   /note="BRCA2 8"
FT   REGION          1..40
FT                   /note="Interaction with PALB2"
FT   REGION          639..1000
FT                   /note="Interaction with NPM1"
FT                   /evidence="ECO:0000269|PubMed:21084279"
FT   REGION          1338..1781
FT                   /note="Interaction with POLH"
FT                   /evidence="ECO:0000269|PubMed:24485656"
FT   REGION          1410..1595
FT                   /note="Required for stimulation of POLH DNA polymerization
FT                   activity"
FT   REGION          2350..2545
FT                   /note="Interaction with FANCD2"
FT   REGION          2481..2832
FT                   /note="Interaction with SEM1"
FT                   /evidence="ECO:0000269|PubMed:10373512,
FT                   ECO:0000269|PubMed:16205630"
FT   MOTIF           2682..2698
FT                   /note="Nuclear export signal; masked by interaction with
FT                   SEM1"
FT                   /evidence="ECO:0000269|PubMed:24013206"
FT   MOD_RES         70
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         492
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         755
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17525332"
FT   MOD_RES         1970
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2035
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         2095
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         3291
FT                   /note="Phosphoserine; by CDK1 and CDK2"
FT                   /evidence="ECO:0000269|PubMed:15800615"
FT   MOD_RES         3319
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         3387
FT                   /note="Phosphothreonine; by CHEK1 and CHEK2"
FT                   /evidence="ECO:0000269|PubMed:18317453"
FT   VARIANT         25
FT                   /note="G -> R (in BC; abolishes interaction with PALB2;
FT                   dbSNP:rs80358961)"
FT                   /evidence="ECO:0000269|PubMed:16793542"
FT                   /id="VAR_028167"
FT   VARIANT         31
FT                   /note="W -> C (in BC; abolishes interaction with PALB2;
FT                   dbSNP:rs80359214)"
FT                   /evidence="ECO:0000269|PubMed:16793542"
FT                   /id="VAR_028168"
FT   VARIANT         31
FT                   /note="W -> R (in BC; abolishes interaction with PALB2;
FT                   dbSNP:rs80359182)"
FT                   /evidence="ECO:0000269|PubMed:16793542"
FT                   /id="VAR_028169"
FT   VARIANT         32
FT                   /note="F -> L (in BC; dbSNP:rs397508057 and
FT                   dbSNP:rs1555280339)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005085"
FT   VARIANT         42
FT                   /note="Y -> C (in BC and ovarian cancer; unknown
FT                   pathological significance; dbSNP:rs4987046)"
FT                   /evidence="ECO:0000269|PubMed:12442275,
FT                   ECO:0000269|PubMed:14746861"
FT                   /id="VAR_020705"
FT   VARIANT         53
FT                   /note="K -> R (in BC; dbSNP:rs397507595)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005086"
FT   VARIANT         60
FT                   /note="N -> S (in BC; unknown pathological significance;
FT                   dbSNP:rs80358463)"
FT                   /evidence="ECO:0000269|PubMed:15026808"
FT                   /id="VAR_020706"
FT   VARIANT         64
FT                   /note="T -> I (in BC; dbSNP:rs397507615)"
FT                   /evidence="ECO:0000269|PubMed:15172753"
FT                   /id="VAR_032712"
FT   VARIANT         75
FT                   /note="A -> P (in ovarian cancer and renal cancer; unknown
FT                   pathological significance; dbSNP:rs28897701)"
FT                   /evidence="ECO:0000269|PubMed:10486320"
FT                   /id="VAR_005087"
FT   VARIANT         81
FT                   /note="F -> L (in BC; dbSNP:rs80358507)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005088"
FT   VARIANT         108
FT                   /note="N -> H (in dbSNP:rs80358567)"
FT                   /id="VAR_008766"
FT   VARIANT         118
FT                   /note="R -> H (in one patient with esophageal carcinoma;
FT                   dbSNP:rs80358603)"
FT                   /evidence="ECO:0000269|PubMed:11948123"
FT                   /id="VAR_032713"
FT   VARIANT         192
FT                   /note="M -> T (in one patient with pancreatic cancer;
FT                   dbSNP:rs80358805)"
FT                   /evidence="ECO:0000269|PubMed:12097290"
FT                   /id="VAR_032714"
FT   VARIANT         201
FT                   /note="P -> R (in BC; dbSNP:rs397507822)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005089"
FT   VARIANT         211
FT                   /note="V -> A (in BC)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005090"
FT   VARIANT         222
FT                   /note="P -> S (in BC; dbSNP:rs397507873)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005091"
FT   VARIANT         225
FT                   /note="T -> A (in one patient with BC; normal RNA
FT                   expression and splicing; dbSNP:rs80358897)"
FT                   /evidence="ECO:0000269|PubMed:15300854"
FT                   /id="VAR_032715"
FT   VARIANT         289
FT                   /note="N -> H (common polymorphism; was originally thought
FT                   to be linked to ovarian cancer; dbSNP:rs766173)"
FT                   /evidence="ECO:0000269|PubMed:10323242,
FT                   ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:11149425"
FT                   /id="VAR_005092"
FT   VARIANT         315
FT                   /note="C -> S (in one patient with esophageal carcinoma;
FT                   dbSNP:rs79483201)"
FT                   /evidence="ECO:0000269|PubMed:11948123"
FT                   /id="VAR_032716"
FT   VARIANT         322
FT                   /note="K -> Q (in dbSNP:rs11571640)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018908"
FT   VARIANT         326
FT                   /note="S -> R (in BC; dbSNP:rs28897706)"
FT                   /evidence="ECO:0000269|PubMed:10399947"
FT                   /id="VAR_032717"
FT   VARIANT         327
FT                   /note="K -> E (in BC; unknown pathological significance;
FT                   dbSNP:rs80359242)"
FT                   /id="VAR_008767"
FT   VARIANT         355
FT                   /note="V -> L (in lung cancer)"
FT                   /id="VAR_005093"
FT   VARIANT         372
FT                   /note="N -> H (common polymorphism; may be associated with
FT                   an increased risk of breast cancer; dbSNP:rs144848)"
FT                   /evidence="ECO:0000269|PubMed:10323242,
FT                   ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:11062481"
FT                   /id="VAR_005094"
FT   VARIANT         405
FT                   /note="G -> R (in BC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:15026808"
FT                   /id="VAR_020707"
FT   VARIANT         431
FT                   /note="T -> I (in BC; unknown pathological significance;
FT                   dbSNP:rs876660828)"
FT                   /evidence="ECO:0000269|PubMed:12938098"
FT                   /id="VAR_020708"
FT   VARIANT         448
FT                   /note="R -> H (in BC; unknown pathological significance;
FT                   dbSNP:rs80358423)"
FT                   /evidence="ECO:0000269|PubMed:15026808"
FT                   /id="VAR_020709"
FT   VARIANT         462
FT                   /note="E -> G (in BC; unknown pathological significance;
FT                   dbSNP:rs56403624)"
FT                   /evidence="ECO:0000269|PubMed:12552570,
FT                   ECO:0000269|PubMed:15026808, ECO:0000269|PubMed:15172753"
FT                   /id="VAR_020710"
FT   VARIANT         505
FT                   /note="I -> T (in BC; dbSNP:rs28897708)"
FT                   /evidence="ECO:0000269|PubMed:11241844"
FT                   /id="VAR_032718"
FT   VARIANT         513
FT                   /note="K -> R (in dbSNP:rs28897709)"
FT                   /id="VAR_056751"
FT   VARIANT         554
FT                   /note="C -> W (in BC and pancreas cancer;
FT                   dbSNP:rs80358451)"
FT                   /evidence="ECO:0000269|PubMed:9654203"
FT                   /id="VAR_005095"
FT   VARIANT         582
FT                   /note="T -> P (in dbSNP:rs80358457)"
FT                   /evidence="ECO:0000269|PubMed:12624724"
FT                   /id="VAR_008768"
FT   VARIANT         598
FT                   /note="T -> A (in dbSNP:rs28897710)"
FT                   /evidence="ECO:0000269|PubMed:12215251"
FT                   /id="VAR_020711"
FT   VARIANT         599
FT                   /note="S -> F (in dbSNP:rs1046984)"
FT                   /evidence="ECO:0000269|PubMed:8589730"
FT                   /id="VAR_035436"
FT   VARIANT         606
FT                   /note="P -> L (in dbSNP:rs80358469)"
FT                   /evidence="ECO:0000269|PubMed:26566883"
FT                   /id="VAR_076440"
FT   VARIANT         613
FT                   /note="L -> R (in BC; unknown pathological significance;
FT                   dbSNP:rs587780646)"
FT                   /evidence="ECO:0000269|PubMed:12442275"
FT                   /id="VAR_020712"
FT   VARIANT         630
FT                   /note="T -> I (in ovarian cancer; dbSNP:rs80358479)"
FT                   /id="VAR_005096"
FT   VARIANT         707
FT                   /note="D -> Y (in dbSNP:rs80358487)"
FT                   /id="VAR_008769"
FT   VARIANT         728
FT                   /note="D -> A (in BC; dbSNP:rs757577670)"
FT                   /id="VAR_005097"
FT   VARIANT         729
FT                   /note="I -> M (in BC; dbSNP:rs397507620)"
FT                   /evidence="ECO:0000269|PubMed:10978364"
FT                   /id="VAR_032719"
FT   VARIANT         784
FT                   /note="M -> V (in dbSNP:rs11571653)"
FT                   /evidence="ECO:0000269|PubMed:11149425,
FT                   ECO:0000269|PubMed:15365993, ECO:0000269|Ref.3"
FT                   /id="VAR_008770"
FT   VARIANT         886
FT                   /note="N -> I (in dbSNP:rs80358526)"
FT                   /id="VAR_008771"
FT   VARIANT         929
FT                   /note="L -> S (in dbSNP:rs2227943)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018909"
FT   VARIANT         935
FT                   /note="D -> N (in BC; unknown pathological significance;
FT                   dbSNP:rs28897716)"
FT                   /id="VAR_008772"
FT   VARIANT         976
FT                   /note="S -> F (in dbSNP:rs11571656)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018910"
FT   VARIANT         982
FT                   /note="I -> L (in dbSNP:rs28897717)"
FT                   /id="VAR_056752"
FT   VARIANT         987
FT                   /note="N -> I (in dbSNP:rs2227944)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018911"
FT   VARIANT         991
FT                   /note="N -> D (common polymorphism; dbSNP:rs1799944)"
FT                   /evidence="ECO:0000269|PubMed:10323242,
FT                   ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:12552570"
FT                   /id="VAR_005098"
FT   VARIANT         1036
FT                   /note="E -> K (in BC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:12938098"
FT                   /id="VAR_020713"
FT   VARIANT         1106
FT                   /note="S -> R (in BC; unknown pathological significance;
FT                   dbSNP:rs1298550035)"
FT                   /evidence="ECO:0000269|PubMed:12938098"
FT                   /id="VAR_020714"
FT   VARIANT         1147
FT                   /note="N -> S (in dbSNP:rs1799951)"
FT                   /evidence="ECO:0000269|PubMed:8673091"
FT                   /id="VAR_005099"
FT   VARIANT         1172
FT                   /note="S -> L (in BC; unknown pathological significance;
FT                   dbSNP:rs80358600)"
FT                   /evidence="ECO:0000269|PubMed:15635067"
FT                   /id="VAR_032720"
FT   VARIANT         1179
FT                   /note="S -> N (in BC; dbSNP:rs397507674)"
FT                   /evidence="ECO:0000269|PubMed:11139248"
FT                   /id="VAR_020715"
FT   VARIANT         1279
FT                   /note="N -> S (in dbSNP:rs1060502384)"
FT                   /evidence="ECO:0000269|PubMed:12552570,
FT                   ECO:0000269|PubMed:15172753"
FT                   /id="VAR_020716"
FT   VARIANT         1286
FT                   /note="Missing"
FT                   /id="VAR_008773"
FT   VARIANT         1290
FT                   /note="C -> Y (in dbSNP:rs41293485)"
FT                   /id="VAR_008774"
FT   VARIANT         1302
FT                   /note="Missing (in BC)"
FT                   /id="VAR_005100"
FT   VARIANT         1414
FT                   /note="T -> M (in dbSNP:rs70953664)"
FT                   /id="VAR_008775"
FT   VARIANT         1420
FT                   /note="D -> Y (in dbSNP:rs28897727)"
FT                   /evidence="ECO:0000269|PubMed:11139248,
FT                   ECO:0000269|PubMed:12215251, ECO:0000269|PubMed:12552570"
FT                   /id="VAR_008776"
FT   VARIANT         1445
FT                   /note="K -> T (in BC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:15365993"
FT                   /id="VAR_020717"
FT   VARIANT         1513
FT                   /note="D -> N (in dbSNP:rs80358687)"
FT                   /id="VAR_008777"
FT   VARIANT         1522
FT                   /note="L -> F (in one patient with BC; dbSNP:rs397507729)"
FT                   /evidence="ECO:0000269|PubMed:12624724"
FT                   /id="VAR_032721"
FT   VARIANT         1524
FT                   /note="F -> V (in BC; unknown pathological significance;
FT                   dbSNP:rs56386506)"
FT                   /evidence="ECO:0000269|PubMed:12938098"
FT                   /id="VAR_020718"
FT   VARIANT         1529
FT                   /note="G -> R (in bladder cancer; dbSNP:rs28897728)"
FT                   /id="VAR_005101"
FT   VARIANT         1542
FT                   /note="V -> M (in dbSNP:rs28897729)"
FT                   /id="VAR_056753"
FT   VARIANT         1561
FT                   /note="H -> N (in dbSNP:rs2219594)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018912"
FT   VARIANT         1580
FT                   /note="C -> Y (in BC; somatic mutation; dbSNP:rs398122784)"
FT                   /evidence="ECO:0000269|PubMed:11948477"
FT                   /id="VAR_020719"
FT   VARIANT         1593
FT                   /note="E -> D (in dbSNP:rs80358703)"
FT                   /evidence="ECO:0000269|PubMed:12442273"
FT                   /id="VAR_008778"
FT   VARIANT         1643
FT                   /note="V -> A (in dbSNP:rs28897731)"
FT                   /id="VAR_056754"
FT   VARIANT         1679
FT                   /note="T -> I (in BC)"
FT                   /evidence="ECO:0000269|PubMed:14722926"
FT                   /id="VAR_020720"
FT   VARIANT         1690
FT                   /note="K -> N (in BC; dbSNP:rs56087561)"
FT                   /evidence="ECO:0000269|PubMed:15172753"
FT                   /id="VAR_032722"
FT   VARIANT         1730
FT                   /note="N -> Y (in BC; dbSNP:rs397507770)"
FT                   /evidence="ECO:0000269|PubMed:11241844"
FT                   /id="VAR_032723"
FT   VARIANT         1771
FT                   /note="G -> D (in BC; unknown pathological significance;
FT                   dbSNP:rs80358755)"
FT                   /evidence="ECO:0000269|PubMed:12552570,
FT                   ECO:0000269|PubMed:15172753"
FT                   /id="VAR_008779"
FT   VARIANT         1804
FT                   /note="V -> A (in BC; dbSNP:rs370252983)"
FT                   /evidence="ECO:0000269|PubMed:14722926"
FT                   /id="VAR_020721"
FT   VARIANT         1805
FT                   /note="N -> S (in dbSNP:rs80358765)"
FT                   /id="VAR_008780"
FT   VARIANT         1880
FT                   /note="N -> K (polymorphism; was originally thought to be
FT                   linked to breast cancer; dbSNP:rs11571657)"
FT                   /evidence="ECO:0000269|PubMed:11241844, ECO:0000269|Ref.3"
FT                   /id="VAR_005102"
FT   VARIANT         1887
FT                   /note="T -> M (in BC; dbSNP:rs397507795)"
FT                   /evidence="ECO:0000269|PubMed:15172753"
FT                   /id="VAR_032724"
FT   VARIANT         1901
FT                   /note="E -> K (in BC)"
FT                   /evidence="ECO:0000269|PubMed:14722926"
FT                   /id="VAR_020722"
FT   VARIANT         1902
FT                   /note="D -> N (in dbSNP:rs4987048)"
FT                   /id="VAR_008781"
FT   VARIANT         1915
FT                   /note="T -> M (may be a rare polymorphism; somatic
FT                   mutation; dbSNP:rs4987117)"
FT                   /evidence="ECO:0000269|PubMed:10978364,
FT                   ECO:0000269|PubMed:11948477, ECO:0000269|PubMed:15172753"
FT                   /id="VAR_005103"
FT   VARIANT         1929
FT                   /note="I -> V (in BC; unknown pathological significance;
FT                   dbSNP:rs79538375)"
FT                   /evidence="ECO:0000269|PubMed:15365993"
FT                   /id="VAR_020723"
FT   VARIANT         1979
FT                   /note="S -> R (in dbSNP:rs28897737)"
FT                   /id="VAR_056755"
FT   VARIANT         1988
FT                   /note="V -> I (in one patient with esophageal carcinoma;
FT                   somatic mutation; dbSNP:rs28897739)"
FT                   /evidence="ECO:0000269|PubMed:11948123"
FT                   /id="VAR_032725"
FT   VARIANT         2031
FT                   /note="T -> A (in BC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:15365993"
FT                   /id="VAR_020724"
FT   VARIANT         2034
FT                   /note="R -> C (in dbSNP:rs1799954)"
FT                   /evidence="ECO:0000269|PubMed:12215251,
FT                   ECO:0000269|PubMed:12569143, ECO:0000269|PubMed:8673091"
FT                   /id="VAR_005104"
FT   VARIANT         2044
FT                   /note="G -> V (in one patient with BC; dbSNP:rs56191579)"
FT                   /evidence="ECO:0000269|PubMed:12624724"
FT                   /id="VAR_032726"
FT   VARIANT         2072
FT                   /note="S -> C (in BC; dbSNP:rs80358862)"
FT                   /evidence="ECO:0000269|PubMed:12373604"
FT                   /id="VAR_020725"
FT   VARIANT         2074
FT                   /note="H -> N (in dbSNP:rs34309943)"
FT                   /id="VAR_008782"
FT   VARIANT         2089
FT                   /note="E -> D (in BC)"
FT                   /evidence="ECO:0000269|PubMed:9150152"
FT                   /id="VAR_008783"
FT   VARIANT         2094
FT                   /note="Y -> C (in BC; dbSNP:rs397507838)"
FT                   /evidence="ECO:0000269|PubMed:12373604"
FT                   /id="VAR_020726"
FT   VARIANT         2096
FT                   /note="P -> L (in BC)"
FT                   /evidence="ECO:0000269|PubMed:14722926"
FT                   /id="VAR_020727"
FT   VARIANT         2108
FT                   /note="R -> C (in dbSNP:rs55794205)"
FT                   /evidence="ECO:0000269|PubMed:15172753"
FT                   /id="VAR_032727"
FT   VARIANT         2116
FT                   /note="H -> R (in dbSNP:rs55953736)"
FT                   /id="VAR_061563"
FT   VARIANT         2118
FT                   /note="V -> L (in BC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:12442275"
FT                   /id="VAR_020728"
FT   VARIANT         2128
FT                   /note="K -> N (in BC; dbSNP:rs397507847)"
FT                   /evidence="ECO:0000269|PubMed:12373604"
FT                   /id="VAR_020729"
FT   VARIANT         2135
FT                   /note="N -> H (in BC; dbSNP:rs80358876)"
FT                   /evidence="ECO:0000269|PubMed:11241844"
FT                   /id="VAR_032728"
FT   VARIANT         2138
FT                   /note="V -> F (in dbSNP:rs11571659)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_008784"
FT   VARIANT         2162
FT                   /note="K -> R (in dbSNP:rs11571660)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018913"
FT   VARIANT         2222
FT                   /note="Y -> C (in BC; dbSNP:rs397507875)"
FT                   /evidence="ECO:0000269|PubMed:11241844"
FT                   /id="VAR_032729"
FT   VARIANT         2238
FT                   /note="D -> E (in dbSNP:rs28897742)"
FT                   /id="VAR_056756"
FT   VARIANT         2274
FT                   /note="G -> V (in BC; dbSNP:rs55712212)"
FT                   /id="VAR_005105"
FT   VARIANT         2275
FT                   /note="E -> G (in BC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:15026808"
FT                   /id="VAR_020730"
FT   VARIANT         2293
FT                   /note="F -> L (in BC; unknown pathological significance;
FT                   dbSNP:rs80358912 and dbSNP:rs1381512588)"
FT                   /evidence="ECO:0000269|PubMed:12442275"
FT                   /id="VAR_020731"
FT   VARIANT         2336
FT                   /note="R -> H (in FANCD1; affects protein splicing and
FT                   expression; decreases homologous recombination-mediated DNA
FT                   repair; dbSNP:rs28897743)"
FT                   /evidence="ECO:0000269|PubMed:16825431,
FT                   ECO:0000269|PubMed:17924331, ECO:0000269|PubMed:21719596"
FT                   /id="VAR_032730"
FT   VARIANT         2336
FT                   /note="R -> Q (in dbSNP:rs28897743)"
FT                   /id="VAR_056757"
FT   VARIANT         2353
FT                   /note="G -> R (in BC; unknown pathological significance;
FT                   dbSNP:rs80358935)"
FT                   /evidence="ECO:0000269|PubMed:15026808"
FT                   /id="VAR_020732"
FT   VARIANT         2415
FT                   /note="H -> N (in BC)"
FT                   /evidence="ECO:0000269|PubMed:8640237"
FT                   /id="VAR_005106"
FT   VARIANT         2421
FT                   /note="Q -> H (in BC)"
FT                   /id="VAR_005107"
FT   VARIANT         2440
FT                   /note="H -> R (polymorphism; no effect on homology-directed
FT                   repair activity; dbSNP:rs4986860)"
FT                   /evidence="ECO:0000269|PubMed:23108138, ECO:0000269|Ref.3"
FT                   /id="VAR_018914"
FT   VARIANT         2447
FT                   /note="N -> D (in dbSNP:rs4986859)"
FT                   /id="VAR_056758"
FT   VARIANT         2456
FT                   /note="Q -> E (in BC; dbSNP:rs397507912)"
FT                   /evidence="ECO:0000269|PubMed:15172753"
FT                   /id="VAR_032731"
FT   VARIANT         2466
FT                   /note="A -> V (polymorphism; was originally thought to be
FT                   linked to ovarian cancer; no effect on homology-directed
FT                   repair activity)"
FT                   /evidence="ECO:0000269|PubMed:12552570,
FT                   ECO:0000269|PubMed:15057823, ECO:0000269|PubMed:15172753"
FT                   /id="VAR_008785"
FT   VARIANT         2480
FT                   /note="L -> V (in dbSNP:rs80358965)"
FT                   /id="VAR_008786"
FT   VARIANT         2488
FT                   /note="R -> K (in BC; unknown pathological significance;
FT                   dbSNP:rs80358968)"
FT                   /evidence="ECO:0000269|PubMed:15026808"
FT                   /id="VAR_020733"
FT   VARIANT         2490
FT                   /note="I -> T (polymorphism; no effect on homologous
FT                   recombination-mediated DNA repair; no effect on interaction
FT                   with SEM1; dbSNP:rs11571707)"
FT                   /evidence="ECO:0000269|PubMed:21719596, ECO:0000269|Ref.3"
FT                   /id="VAR_008787"
FT   VARIANT         2502
FT                   /note="R -> C (in BC; unknown pathological significance;
FT                   dbSNP:rs55716624)"
FT                   /evidence="ECO:0000269|PubMed:17924331"
FT                   /id="VAR_063911"
FT   VARIANT         2502
FT                   /note="R -> H (in ovarian cancer; unknown pathological
FT                   significance; dbSNP:rs56070345)"
FT                   /evidence="ECO:0000269|PubMed:10486320"
FT                   /id="VAR_008788"
FT   VARIANT         2510
FT                   /note="L -> P (in FANCD1; hypersensitive to DNA damage;
FT                   disrupts interaction with SEM1; decreased homology-directed
FT                   repair activity; dbSNP:rs80358979)"
FT                   /evidence="ECO:0000269|PubMed:14670928,
FT                   ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_032732"
FT   VARIANT         2515
FT                   /note="T -> I (in BC; unknown pathological significance;
FT                   dbSNP:rs28897744)"
FT                   /evidence="ECO:0000269|PubMed:10978364"
FT                   /id="VAR_008789"
FT   VARIANT         2626
FT                   /note="W -> C (in FANCD1; hypersensitive to DNA damage;
FT                   reduced homology-directed repair activity; no effect on
FT                   interaction with SEM1; dbSNP:rs80359013)"
FT                   /evidence="ECO:0000269|PubMed:16825431,
FT                   ECO:0000269|PubMed:17924331, ECO:0000269|PubMed:21719596"
FT                   /id="VAR_032733"
FT   VARIANT         2627
FT                   /note="I -> F (in BC; unknown pathological significance;
FT                   reduced homology-directed repair activity;
FT                   dbSNP:rs80359014)"
FT                   /evidence="ECO:0000269|PubMed:17924331,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_063912"
FT   VARIANT         2653
FT                   /note="L -> P (in BC; unknown pathological significance;
FT                   reduced homology-directed repair activity;
FT                   dbSNP:rs80359022)"
FT                   /evidence="ECO:0000269|PubMed:17924331,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_063913"
FT   VARIANT         2659
FT                   /note="R -> K (in BC; unknown pathological significance;
FT                   dbSNP:rs80359027)"
FT                   /evidence="ECO:0000269|PubMed:17924331"
FT                   /id="VAR_063914"
FT   VARIANT         2663
FT                   /note="E -> V (could be associated with cancer
FT                   susceptibility; major splicing aberration identified with
FT                   this mutant; multifactorial likelihood analysis provides
FT                   evidence for pathogenicity; dbSNP:rs80359031)"
FT                   /evidence="ECO:0000269|PubMed:17924331,
FT                   ECO:0000269|PubMed:20513136"
FT                   /id="VAR_063915"
FT   VARIANT         2686
FT                   /note="L -> P (in dbSNP:rs28897746)"
FT                   /id="VAR_056759"
FT   VARIANT         2706
FT                   /note="N -> S (in dbSNP:rs80359055)"
FT                   /evidence="ECO:0000269|PubMed:12442273"
FT                   /id="VAR_020734"
FT   VARIANT         2722
FT                   /note="T -> R (in BC; reduced homology-directed repair
FT                   activity; dbSNP:rs80359062)"
FT                   /evidence="ECO:0000269|PubMed:12145750,
FT                   ECO:0000269|PubMed:17924331, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_018661"
FT   VARIANT         2723
FT                   /note="D -> G (in BC; has defective function consistent
FT                   with pathogenicity; major splicing aberration identified
FT                   with this mutant; reduced homology-directed repair
FT                   activity; dbSNP:rs41293513)"
FT                   /evidence="ECO:0000269|PubMed:17924331,
FT                   ECO:0000269|PubMed:20513136, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_063916"
FT   VARIANT         2723
FT                   /note="D -> H (in BC; unknown pathological significance;
FT                   disrupts interaction with SEM1 promoting interaction with
FT                   XPO1 and BRCA2 cytoplasmic localization; in heterozygous
FT                   state promotes RAD51 cytoplasmic localization; reduced
FT                   homology-directed repair activity; dbSNP:rs41293511)"
FT                   /evidence="ECO:0000269|PubMed:15026808,
FT                   ECO:0000269|PubMed:23108138, ECO:0000269|PubMed:24013206"
FT                   /id="VAR_020735"
FT   VARIANT         2728
FT                   /note="V -> I (in BC; dbSNP:rs28897749)"
FT                   /evidence="ECO:0000269|PubMed:10399947,
FT                   ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:12215251"
FT                   /id="VAR_020736"
FT   VARIANT         2729
FT                   /note="K -> N (in BC; unknown pathological significance; no
FT                   effect on homologous recombination-mediated DNA repair; no
FT                   effect on interaction with SEM1; dbSNP:rs80359065)"
FT                   /evidence="ECO:0000269|PubMed:12442274,
FT                   ECO:0000269|PubMed:21719596, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_020737"
FT   VARIANT         2748
FT                   /note="G -> D (in BC; unknown pathological significance;
FT                   dbSNP:rs80359071)"
FT                   /evidence="ECO:0000269|PubMed:17924331"
FT                   /id="VAR_063917"
FT   VARIANT         2787
FT                   /note="R -> H (in ovarian cancer and BC; somatic mutation;
FT                   unknown pathological significance; small decrease of
FT                   homology-directed repair activity; dbSNP:rs80359078)"
FT                   /evidence="ECO:0000269|PubMed:23108138,
FT                   ECO:0000269|PubMed:8665505"
FT                   /id="VAR_008790"
FT   VARIANT         2792
FT                   /note="L -> P (in BC; unknown pathological significance;
FT                   decreased homology-directed repair activity;
FT                   dbSNP:rs28897751)"
FT                   /evidence="ECO:0000269|PubMed:23108138"
FT                   /id="VAR_056760"
FT   VARIANT         2793
FT                   /note="G -> R (in BC; unknown pathological significance;
FT                   decreased homology-directed repair activity;
FT                   dbSNP:rs80359082)"
FT                   /evidence="ECO:0000269|PubMed:12442275,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_020738"
FT   VARIANT         2835
FT                   /note="S -> P (in dbSNP:rs11571746)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018915"
FT   VARIANT         2842
FT                   /note="R -> C (in one patient with esophageal carcinoma;
FT                   somatic mutation; decreased homology-directed repair
FT                   activity; dbSNP:rs80359104)"
FT                   /evidence="ECO:0000269|PubMed:11948123,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_032734"
FT   VARIANT         2856
FT                   /note="E -> A (in BC; unknown pathological significance; no
FT                   effect on homology-directed repair activity;
FT                   dbSNP:rs11571747)"
FT                   /evidence="ECO:0000269|PubMed:15026808,
FT                   ECO:0000269|PubMed:23108138, ECO:0000269|Ref.3"
FT                   /id="VAR_018916"
FT   VARIANT         2944
FT                   /note="I -> F (in dbSNP:rs4987047)"
FT                   /evidence="ECO:0000269|PubMed:15635067, ECO:0000269|Ref.3"
FT                   /id="VAR_008791"
FT   VARIANT         2950
FT                   /note="K -> N (in BC; unknown pathological significance;
FT                   dbSNP:rs28897754)"
FT                   /evidence="ECO:0000269|PubMed:15026808,
FT                   ECO:0000269|PubMed:15635067"
FT                   /id="VAR_020739"
FT   VARIANT         2951
FT                   /note="A -> T (in BC; unknown pathological significance; no
FT                   effect on homology-directed repair activity;
FT                   dbSNP:rs11571769)"
FT                   /evidence="ECO:0000269|PubMed:12215251,
FT                   ECO:0000269|PubMed:23108138, ECO:0000269|Ref.3"
FT                   /id="VAR_008792"
FT   VARIANT         2969
FT                   /note="V -> M (in dbSNP:rs59004709)"
FT                   /id="VAR_008793"
FT   VARIANT         3013
FT                   /note="T -> I (in BC; unknown pathological significance; no
FT                   effect on homology-directed repair activity;
FT                   dbSNP:rs28897755)"
FT                   /evidence="ECO:0000269|PubMed:15026808,
FT                   ECO:0000269|PubMed:15635067, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_020740"
FT   VARIANT         3052
FT                   /note="R -> W (in BC; has defective function consistent
FT                   with pathogenicity; multifactorial likelihood analysis
FT                   provides evidence for pathogenicity; reduced homology-
FT                   directed repair activity; dbSNP:rs45580035)"
FT                   /evidence="ECO:0000269|PubMed:20513136,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_063918"
FT   VARIANT         3063
FT                   /note="P -> S (in a patient with ovarian cancer; unknown
FT                   pathological significance; no effect on homology-directed
FT                   repair activity; dbSNP:rs80359176)"
FT                   /evidence="ECO:0000269|PubMed:14746861,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_020741"
FT   VARIANT         3076
FT                   /note="G -> E (in BC; also found in pancreatic cancer;
FT                   decreased homology-directed repair activity;
FT                   dbSNP:rs80359187)"
FT                   /evidence="ECO:0000269|PubMed:11149425,
FT                   ECO:0000269|PubMed:12569143, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_020742"
FT   VARIANT         3095
FT                   /note="D -> E (in BC; unknown pathological significance;
FT                   reduced homology-directed repair activity;
FT                   dbSNP:rs80359198)"
FT                   /evidence="ECO:0000269|PubMed:17924331,
FT                   ECO:0000269|PubMed:23108138, ECO:0000269|PubMed:8640235"
FT                   /id="VAR_005108"
FT   VARIANT         3098
FT                   /note="Y -> H (in BC and ovarian cancer; unknown
FT                   pathological significance; no effect on homology-directed
FT                   repair activity; dbSNP:rs41293521)"
FT                   /evidence="ECO:0000269|PubMed:10486320,
FT                   ECO:0000269|PubMed:15026808, ECO:0000269|PubMed:23108138"
FT                   /id="VAR_008794"
FT   VARIANT         3101
FT                   /note="L -> R (in dbSNP:rs28897758)"
FT                   /id="VAR_056761"
FT   VARIANT         3103
FT                   /note="I -> M (in melanoma; dbSNP:rs80359204)"
FT                   /id="VAR_005109"
FT   VARIANT         3118
FT                   /note="M -> T (in BC; dbSNP:rs56204128)"
FT                   /evidence="ECO:0000269|PubMed:9609997"
FT                   /id="VAR_005110"
FT   VARIANT         3124
FT                   /note="N -> I (in BC; reduced homology-directed repair
FT                   activity; dbSNP:rs28897759)"
FT                   /evidence="ECO:0000269|PubMed:11139248,
FT                   ECO:0000269|PubMed:23108138"
FT                   /id="VAR_020743"
FT   VARIANT         3196
FT                   /note="K -> E (in BC; dbSNP:rs80359228)"
FT                   /evidence="ECO:0000269|PubMed:11139248"
FT                   /id="VAR_020744"
FT   VARIANT         3244
FT                   /note="V -> I (in dbSNP:rs11571831)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018917"
FT   VARIANT         3257
FT                   /note="K -> R (in dbSNP:rs55847618)"
FT                   /id="VAR_008795"
FT   VARIANT         3276
FT                   /note="R -> S (in dbSNP:rs80359245)"
FT                   /id="VAR_008796"
FT   VARIANT         3300
FT                   /note="P -> S (in one patient with esophageal carcinoma;
FT                   dbSNP:rs770868371)"
FT                   /evidence="ECO:0000269|PubMed:11948123"
FT                   /id="VAR_032735"
FT   VARIANT         3357
FT                   /note="T -> R (in BC; dbSNP:rs80358388)"
FT                   /id="VAR_005111"
FT   VARIANT         3374
FT                   /note="T -> I (in dbSNP:rs56309455)"
FT                   /evidence="ECO:0000269|PubMed:12442275"
FT                   /id="VAR_020745"
FT   VARIANT         3412
FT                   /note="I -> V (polymorphism; was originally thought to be
FT                   associated with breast cancer; dbSNP:rs1801426)"
FT                   /evidence="ECO:0000269|PubMed:10323242,
FT                   ECO:0000269|PubMed:10978364, ECO:0000269|PubMed:12442274"
FT                   /id="VAR_005112"
FT   MUTAGEN         2725
FT                   /note="W->A: Disrupts interaction with SEM1"
FT                   /evidence="ECO:0000269|PubMed:24013206"
FT   MUTAGEN         3291
FT                   /note="S->E: Impaired interaction with RAD51"
FT                   /evidence="ECO:0000269|PubMed:15800615"
FT   MUTAGEN         3387
FT                   /note="T->A: Loss of phosphorylation by CHEK1 and CHEK2 (in
FT                   vitro)"
FT                   /evidence="ECO:0000269|PubMed:18317453"
FT   CONFLICT        758
FT                   /note="S -> N (in Ref. 1; CAA64484)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1761..1762
FT                   /note="GY -> RI (in Ref. 1; CAA64484)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1767
FT                   /note="K -> N (in Ref. 1; CAA64484)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2536
FT                   /note="S -> P (in Ref. 4; CAA98995)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        3216
FT                   /note="L -> LVS (in Ref. 4; CAA97728)"
FT                   /evidence="ECO:0000305"
FT   HELIX           31..35
FT                   /evidence="ECO:0000244|PDB:3EU7"
FT   HELIX           1520..1522
FT                   /evidence="ECO:0000244|PDB:1N0W"
FT   HELIX           1536..1541
FT                   /evidence="ECO:0000244|PDB:1N0W"
FT   TURN            1542..1546
FT                   /evidence="ECO:0000244|PDB:1N0W"
SQ   SEQUENCE   3418 AA;  384202 MW;  6A0B3B7B332153EB CRC64;
     MPIGSKERPT FFEIFKTRCN KADLGPISLN WFEELSSEAP PYNSEPAEES EHKNNNYEPN
     LFKTPQRKPS YNQLASTPII FKEQGLTLPL YQSPVKELDK FKLDLGRNVP NSRHKSLRTV
     KTKMDQADDV SCPLLNSCLS ESPVVLQCTH VTPQRDKSVV CGSLFHTPKF VKGRQTPKHI
     SESLGAEVDP DMSWSSSLAT PPTLSSTVLI VRNEEASETV FPHDTTANVK SYFSNHDESL
     KKNDRFIASV TDSENTNQRE AASHGFGKTS GNSFKVNSCK DHIGKSMPNV LEDEVYETVV
     DTSEEDSFSL CFSKCRTKNL QKVRTSKTRK KIFHEANADE CEKSKNQVKE KYSFVSEVEP
     NDTDPLDSNV ANQKPFESGS DKISKEVVPS LACEWSQLTL SGLNGAQMEK IPLLHISSCD
     QNISEKDLLD TENKRKKDFL TSENSLPRIS SLPKSEKPLN EETVVNKRDE EQHLESHTDC
     ILAVKQAISG TSPVASSFQG IKKSIFRIRE SPKETFNASF SGHMTDPNFK KETEASESGL
     EIHTVCSQKE DSLCPNLIDN GSWPATTTQN SVALKNAGLI STLKKKTNKF IYAIHDETSY
     KGKKIPKDQK SELINCSAQF EANAFEAPLT FANADSGLLH SSVKRSCSQN DSEEPTLSLT
     SSFGTILRKC SRNETCSNNT VISQDLDYKE AKCNKEKLQL FITPEADSLS CLQEGQCEND
     PKSKKVSDIK EEVLAAACHP VQHSKVEYSD TDFQSQKSLL YDHENASTLI LTPTSKDVLS
     NLVMISRGKE SYKMSDKLKG NNYESDVELT KNIPMEKNQD VCALNENYKN VELLPPEKYM
     RVASPSRKVQ FNQNTNLRVI QKNQEETTSI SKITVNPDSE ELFSDNENNF VFQVANERNN
     LALGNTKELH ETDLTCVNEP IFKNSTMVLY GDTGDKQATQ VSIKKDLVYV LAEENKNSVK
     QHIKMTLGQD LKSDISLNID KIPEKNNDYM NKWAGLLGPI SNHSFGGSFR TASNKEIKLS
     EHNIKKSKMF FKDIEEQYPT SLACVEIVNT LALDNQKKLS KPQSINTVSA HLQSSVVVSD
     CKNSHITPQM LFSKQDFNSN HNLTPSQKAE ITELSTILEE SGSQFEFTQF RKPSYILQKS
     TFEVPENQMT ILKTTSEECR DADLHVIMNA PSIGQVDSSK QFEGTVEIKR KFAGLLKNDC
     NKSASGYLTD ENEVGFRGFY SAHGTKLNVS TEALQKAVKL FSDIENISEE TSAEVHPISL
     SSSKCHDSVV SMFKIENHND KTVSEKNNKC QLILQNNIEM TTGTFVEEIT ENYKRNTENE
     DNKYTAASRN SHNLEFDGSD SSKNDTVCIH KDETDLLFTD QHNICLKLSG QFMKEGNTQI
     KEDLSDLTFL EVAKAQEACH GNTSNKEQLT ATKTEQNIKD FETSDTFFQT ASGKNISVAK
     ESFNKIVNFF DQKPEELHNF SLNSELHSDI RKNKMDILSY EETDIVKHKI LKESVPVGTG
     NQLVTFQGQP ERDEKIKEPT LLGFHTASGK KVKIAKESLD KVKNLFDEKE QGTSEITSFS
     HQWAKTLKYR EACKDLELAC ETIEITAAPK CKEMQNSLNN DKNLVSIETV VPPKLLSDNL
     CRQTENLKTS KSIFLKVKVH ENVEKETAKS PATCYTNQSP YSVIENSALA FYTSCSRKTS
     VSQTSLLEAK KWLREGIFDG QPERINTADY VGNYLYENNS NSTIAENDKN HLSEKQDTYL
     SNSSMSNSYS YHSDEVYNDS GYLSKNKLDS GIEPVLKNVE DQKNTSFSKV ISNVKDANAY
     PQTVNEDICV EELVTSSSPC KNKNAAIKLS ISNSNNFEVG PPAFRIASGK IVCVSHETIK
     KVKDIFTDSF SKVIKENNEN KSKICQTKIM AGCYEALDDS EDILHNSLDN DECSTHSHKV
     FADIQSEEIL QHNQNMSGLE KVSKISPCDV SLETSDICKC SIGKLHKSVS SANTCGIFST
     ASGKSVQVSD ASLQNARQVF SEIEDSTKQV FSKVLFKSNE HSDQLTREEN TAIRTPEHLI
     SQKGFSYNVV NSSAFSGFST ASGKQVSILE SSLHKVKGVL EEFDLIRTEH SLHYSPTSRQ
     NVSKILPRVD KRNPEHCVNS EMEKTCSKEF KLSNNLNVEG GSSENNHSIK VSPYLSQFQQ
     DKQQLVLGTK VSLVENIHVL GKEQASPKNV KMEIGKTETF SDVPVKTNIE VCSTYSKDSE
     NYFETEAVEI AKAFMEDDEL TDSKLPSHAT HSLFTCPENE EMVLSNSRIG KRRGEPLILV
     GEPSIKRNLL NEFDRIIENQ EKSLKASKST PDGTIKDRRL FMHHVSLEPI TCVPFRTTKE
     RQEIQNPNFT APGQEFLSKS HLYEHLTLEK SSSNLAVSGH PFYQVSATRN EKMRHLITTG
     RPTKVFVPPF KTKSHFHRVE QCVRNINLEE NRQKQNIDGH GSDDSKNKIN DNEIHQFNKN
     NSNQAAAVTF TKCEEEPLDL ITSLQNARDI QDMRIKKKQR QRVFPQPGSL YLAKTSTLPR
     ISLKAAVGGQ VPSACSHKQL YTYGVSKHCI KINSKNAESF QFHTEDYFGK ESLWTGKGIQ
     LADGGWLIPS NDGKAGKEEF YRALCDTPGV DPKLISRIWV YNHYRWIIWK LAAMECAFPK
     EFANRCLSPE RVLLQLKYRY DTEIDRSRRS AIKKIMERDD TAAKTLVLCV SDIISLSANI
     SETSSNKTSS ADTQKVAIIE LTDGWYAVKA QLDPPLLAVL KNGRLTVGQK IILHGAELVG
     SPDACTPLEA PESLMLKISA NSTRPARWYT KLGFFPDPRP FPLPLSSLFS DGGNVGCVDV
     IIQRAYPIQW MEKTSSGLYI FRNEREEEKE AAKYVEAQQK RLEALFTKIQ EEFEEHEENT
     TKPYLPSRAL TRQQVRALQD GAELYEAVKN AADPAYLEGY FSEEQLRALN NHRQMLNDKK
     QAQIQLEIRK AMESAEQKEQ GLSRDVTTVW KLRIVSYSKK EKDSVILSIW RPSSDLYSLL
     TEGKRYRIYH LATSKSKSKS ERANIQLAAT KKTQYQQLPV SDEILFQIYQ PREPLHFSKF
     LDPDFQPSCS EVDLIGFVVS VVKKTGLAPF VYLSDECYNL LAIKFWIDLN EDIIKPHMLI
     AASNLQWRPE SKSGLLTLFA GDFSVFSASP KEGHFQETFN KMKNTVENID ILCNEAENKL
     MHILHANDPK WSTPTKDCTS GPYTAQIIPG TGNKLLMSSP NCEIYYQSPL SLCMAKRKSV
     STPVSAQMTS KSCKGEKEID DQKNCKKRRA LDFLSRLPLP PPVSPICTFV SPAAQKAFQP
     PRSCGTKYET PIKKKELNSP QMTPFKKFNE ISLLESNSIA DEELALINTQ ALLSGSTGEK
     QFISVSESTR TAPTSSEDYL RLKRRCTTSL IKEQESSQAS TEECEKNKQD TITTKKYI
//